Biomarker and pathology studies in neurodegenerative cognitive impairment by Skogseth, Ragnhild Eide
Ragnhild Eide Skogseth




Thesis for the degree of Philosophiae Doctor (PhD)
University of Bergen, Norway
at the University of Bergen
Avhandling for graden philosophiae doctor (ph.d )
ved Universitetet i ergen
.
2017
Dato for disputas: 1111
Ragnhild Eide Skogseth
Biomarker and pathology studies in
neurodegenerative cognitive impairment
Thesis for the de ree of P il i  Doctor (PhD)
Date of defense: 16.10.2019
The material in this publication is covered by the provisions of the Copyright Act.
Print:     Skipnes Kommunikasjon / University of Bergen
© Copyright Ragnhild Eide Skogseth
Name:        Ragnhild Eide Skogseth
Title: Biomarker and pathology studies in neurodegenerative cognitive impairment
Year:          2019
 
© Copyright Ragnhild Eide Skogseth 
Materialet i denne publikasjonen er omfattet av åndverkslovens bestemmelser.  
 
År: 2019 
Tittel: Biomarker and pathology studies in neurodegenerative cognitive impairment 
Forfatter: Ragnhild Eide Skogseth!



















































































This project started while I was a medical student at the Research Program at the University 
of Bergen. I have been part of the Dementia Study of Western Norway (Demvest) study group 
from the start in 2005. The majority of the work has been conducted at Haraldsplass 
Deaconess Hospital, in combination with a 50% resident position with the department of 
Geriatric Medicine. In addition to Haraldsplass Deaconess Hospital my affiliations include 
Department of Clinical Medicine at the University of Bergen, The Kavli Centre for Geriatrics 
and Dementia and SESAM – Centre for Age-related Medicine.  
 
 
   
 
 
   
 
Acknowledgements(
First of all, I would like to thank all patients and carers who contributed to the 
Demvest and Parkinson’s Markers Initiative project (PPMI). The gifts of your time 
and effort, cerebrospinal fluid and brain tissue are very highly appreciated. I’m also 
grateful for all the other patients with dementia I have met along the way who have 
taught and continue to teach me important lessons about dementia. The stoicism and 
courage of both patients and carers continually impresses me.  
 
I would like to thank my main supervisor, Dag Årsland for all his help and support. 
For all his enthusiasm, constructive input on texts and ideas and our conversations 
about the extremely fascinating field that is dementia and dementia research.  
 
I am also very grateful for the help of my co-supervisors, Nils Erik Gilhus and Tormod 
Fladby. Nils Erik Gilhus’ long experience with research and research administration 
has been invaluable. The input from my coauthors; Ezra Mulugeta, Clive Ballard, 
Sabine Nore, Guido Alves, Kolbjørn Brønnick, Joana Braga Pereira, Brit Möllenhauer, 
Daniel Weintraub, Tormod Fladby, Tibor Hortobágyi, Hogne Sønnesyn, Luiza 
Jadwiga Chwiszczuk, and Dominic Ffytche has been invaluable. 
  
I am indebted to Haraldsplass Deaconess Hospital for funding my work. Thanks you 
to my coworkers in the Department of Internal Medicine in general, in particular my 
great colleagues in the Department of Geriatric Medicine. I’ve learned so much from 
you all, and you´ve been so important for me these years while working on my thesis. 
In particular I´d like to mention Mala Naik for invaluable advice in dementia 
diagnostics, my clinical supervisor Paal Naalsund, and Alison Deuis for excellent 
proofreading. 
 
Thank you also to everyone involved in the Demvest project. To date, the project has 
been running for 14 years, and it has demanded a lot of effort from everyone involved. 




administrative personnel. From Haraldsplass Deaconess Hospital, I’d especially like to 
thank Kari Espedal and Randi Fauskanger, excellent research nurses with long 
experience in geriatric medicine and physicians Paal Naalsund, Mala Naik and Sabine 
Nore for careful patient assessments.  
 
I would also like to thank Michael J. Fox and everyone involved in the PPMI project. 
To make the data available to researcher all around the world is a progressive action 
that will lead to advancement in PD research.  
 
Thank you also to the Geriatric research environment in Bergen; Ida Kristine Sangnes, 
Katinka Alme, Ole Martin Steihaug, Frøydis Bruvik, Marit Bakken, Susanne Hernes, 
Elisabeth Skaar, Anette Hylen Ranhoff and Lasse Giil – your input has been much 
appreciated.  
 
I am also very grateful for all the help from my parents and parents in law, without 
your support and babysitting this long project would have been even longer… And last 
but definitely not least – Astrid and Sigrid for being perfect distractions from research 













Biomarker and pathology studies in neurodegenerative cognitive impairment  
 
Background: Dementia is a major cause of functional impairment and early death in 
older age groups. Neurodegenerative disorders are the most common cause of 
dementia. The most frequent neuropathological lesions include neurofibrillary tangles 
and senile plaques, hallmark lesions for Alzheimer´s disease (AD), and Lewy body 
pathology, which characterize Lewy body disease (LBD). Clinically, the 
neuropathological entity LBD can present as either Parkinson´s disease (PD) or 
dementia with Lewy bodies (DLB), differentiated on the basis of the presenting  
symptoms being either motor or cognitive. While the majority of LBD patients 
develop both motor symptoms and cognitive impairment, some patients with clinical 
PD will never experience cognitive impairment and likewise some patients with DLB 
will never develop motor symptoms.  
 
Similarly the clinical presentation of AD is also heterogeneous, for instance, the highly 
variable occurrence of neuropsychiatric symptoms and rate of progression. These 
differences have a major impact on quality of life for patients and carers, as well as 
health care costs, but their mechanisms and neuropathological underpinnings are 
poorly understood. Furthermore the correlation between clinical diagnosis and 
neuropathological findings is relatively low, and LBD patients presenting with 
cognitive impairment particularly risk being misclassified as AD. This highlight the 
need for more precise biomarkers for these clinical syndromes that can be 
implemented at the start of and during the course of the disease.  
 
Biomarkers may inform about disease pathology, thus paving the way for new 
treatment, they increase diagnostic accuracy and aid in setting a prognosis. Biomarkers 
are needed in the selection of patients for treatment studies and to identify which 
patients should benefit from new treatment when available. The cerebrospinal fluid 
(CSF) biomarkers beta-amyloid 42 (abeta42), total tau (t-tau) and tau protein 




bodies found in LBD are composed mainly of the protein !-synuclein. !-synuclein is 
reduced in CSF in LBD, but with considerable overlap between LBD, controls and 
other disease groups.  
 
Aim: The main aim of this thesis was to increase understanding of pathological 
mechanisms underlying important clinical features in neurodegenerative cognitive 
impairment, by exploring the associations between clinical presentation and 
biomarkers and pathology. The first objective was to explore the association between 
AD pathology CSF markers and neuropsychiatric symptoms in newly diagnosed AD 
patients; secondly to assess the association between CSF markers of AD and LBD 
pathology and early cognitive impairment in PD; thirdly to examine the correlation 
between clinical diagnosis of DLB and Lewy body pathology at autopsy. 
 
Methods: This is a clinical translational neuroscience project based on two clinical 
cohort studies. The dementia Study of Western Norway (Demvest) included newly 
diagnosed dementia patients from specialist clinics in geriatric medicine and old age 
psychiatry in Western Norway. The Parkinson´s Progression Markers Initiative 
(PPMI) is an international multicentre study, including newly diagnosed PD patients 
and healthy controls. A comprehensive battery of neuropsychological tests, a 
structured neuropsychiatric evaluation, clinical examination, and imaging were part of 
both studies. CSF sampling was done according to standardized protocols and CSF 
was analysed using commercially available immunoassays. In the Demvest study, 
participants were recruited for brain donation, and autopsy results were obtained 
applying commonly used neuropathological protocols and diagnostic criteria.  
 
Results: We undertook three specific studies to investigate objective I, II and III. In 
study I, apathy in patients with early Alzheimer´s disease correlated with t-tau and p-
tau181 concentrations in CSF, higher values being associated with more severe apathy. 






In study II, decreased CSF !-synuclein in newly diagnosed PD-patients without 
dementia correlated with impaired global cognition and impairment of executive 
functions and attention. CSF abeta42 was decreased in PD with mild cognitive 
impairment compared with controls after adjusting for covariates. No correlations 
were found between memory or visuospatial functions and CSF markers.  
 
Study III examined autopsy results of 56 patients followed from dementia diagnosis to 
death. 20 patients received a pathological diagnosis of LBD; the corresponding clinical 
diagnosis were probable DLB (n=11), Parkinson´s disease with dementia (PDD) (n=5) 
and probable or possible AD (n=4). Of the 56, 14 patients received a clinical diagnosis 
of probable DLB, 11 of these had pathological LBD and three AD. Sensitivity, 
specificity, positive and negative predictive values of a clinical DLB diagnosis were 
73%, 93%, 70%, and 90% respectively.  
 
Conclusions and implications: We have reported a novel association between 
neuropsychiatric symptoms and CSF biomarkers reflecting core AD pathology. The 
relationship between t-tau and p-tau181 and apathy may reflect an association between 
neurofibrillary tangle pathology and apathy in early AD.  
 
Cognitive impairment in early PD was associated with biomarkers of both Lewy body 
and AD pathology. 18 of 20 LBD patients in the Demvest study had Braak 
neurofibrillary tangle stage IV or higher, representing severe AD pathology at autopsy. 
Thus our findings suggest a role for AD pathology in both early and established LBD.  
  
Accurate diagnosis is crucial for clinical practice and research. With a sensitivity of 
73%, the clinical 2005 DLB criteria are not sensitive enough. More than one in four 
DLB patients were not identified even when structured rating scales for core DLB 
symptoms were applied. We regard a specificity of 93% as satisfactory. Our results 
illustrate that not all DLB patients fulfil the 2005 DLB criteria at disease presentation, 




Studies applying the most recent 2017 DLB criteria will show if this revision has 
increased sensitivity without decreasing specificity.  
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Abeta peptides: Beta-amyloid peptides, abeta42 has 42 amino acids, abeta40 has 40 
amino acids.  
AD-MCI: MCI patients who develop AD 
AD: Alzheimer’s disease 
ADL: Activities of daily living 
APOE: The gene that codes for Apolipoprotein E 
CERAD: The Consortium to Establish a Registry for Alzheimer´s disease 
CSF: Cerebrospinal fluid 
CV: Coefficient of variation 
DAT imaging: Dopamine Transporter Imaging 
Demvest: The Dementia Study of Western Norway 
DLB-MCI: MCI patients who develop DLB 
DLB: Dementia with Lewy bodies 
DSM: Diagnostic and Statistical Manual of Mental Disorders 
ELISA: Enzyme linked immunosorbent assay 
FDG-PET: 18F-Fluorodeoxyglucose positron emission tomography 
FTD: Frontotemporal dementia 
GBA: The gene that codes for the enzyme beta-glucocerebrosidase  
HLVT: Hopkins Verbal Learning Test  
ICD-10: International Statistical Classification of Diseases and Related Health 
Problems, 10th edition 
IQCODE: Informant Questionnaire on Cognitive Decline in the Elderly 
LBD: Lewy body disease – Parkinson’s disease and dementia with Lewy bodies 
LRRK2: Leucine-rich repeat kinase 2 
MCI: Mild cognitive impairment 
mL: Milliliter 
MMSE: Mini-Mental State Evaluation 
MoCA: Montreal Cognitive Assessment 




NPI: Neuropsychiatric Inventory 
OR: Odds ratio 
p-tau181: Tau protein phosphorylated at amino acid number 181 
PD-MCI: Parkinson’s disease with mild cognitive impairment 
PD: Parkinson’s disease 
PDD: Parkinson’s disease with dementia 
PiB-PET: 11C-PiB, Pittsburgh Compound B. PET tracer that bind to beta-amyloid 
plaques 
PPMI: Parkinson`s Progression Markers Initiative 
PSA: Progressive supranuclear palsy 
RBD: REM Sleep Behavior Disorder 
SD: Standard deviation 
t-tau: Total tau protein 
UPDRS: Unified Parkinson´s Disease Rating Scale  





Dementia is common. The number of people living with dementia was estimated to be 
47 million in 2015 and is expected to increase to 66 million by 2030 and 131 million 
by 20501. Whilst the prevalence is increasing due to aging populations, there is some 
evidence that the incidence is decreasing in industrialized countries1-3. This might be 
caused by both decreased incidence and better treatment of dementia risk factors such 
as hypertension, diabetes, smoking, and cerebrovascular disease and increased 
exposure to protective influences such as a healthy lifestyle, balanced diet and 
education1, 3. Dementia has major consequences for both the individuals affected, and 
their family and carers, as well as being associated with high costs in both primary and 
secondary health care settings1.  
 
According to the clinical International Statistical Classifications of Diseases and 
Health Related Problems (ICD-10) by the World Health Organization4;  
 
Dementia is a syndrome due to disease of the brain, usually of a chronic or 
progressive nature, in which there is disturbance of multiple higher cortical 
functions, including memory, thinking, orientation, comprehension, calculation, 
learning capacity, language, and judgement. Consciousness is not clouded. The 
impairments of cognitive function are commonly accompanied, and 
occasionally preceded, by deterioration in emotional control, social behaviour, 
or motivation. 
 
It is also specified that the syndrome affects activities of daily living. AD, vascular 
dementia (VaD), DLB and mixed dementia are the most common causes of dementia1. 
Frontotemporal dementia (FTD) is less common overall, but relatively more common 




body pathology; therefore they are commonly referred to as Lewy body diseases 
(LBD)5.   
 
AD and LBD are neurodegenerative disorders with heterogeneous clinical 
presentations. There are major differences in symptoms and disease course between 
individuals with the same condition. The mechanisms and neuropathology underlying 
these differences are poorly understood. Interestingly, AD and LBD with dementia 
share many clinical features, furthermore, at the neuropathological examination the 
combination of AD and LBD pathology is common.  
1.2" Biomarkers"
A biomarker can be defined as “a characteristic that is objectively measured and 
evaluated as an indicator of normal biological processes, pathogenic processes or 
pharmacologic responses to a therapeutic intervention”6. Biomarkers can be used to 
predict future disease at the pre-clinical stage, give information about prognosis, 
increase diagnostic accuracy or predict treatment response7. Biomarkers and detailed 
neuropathological examinations can aid in elucidating the differences and similarities 
between AD and LBD, and support the clinical management and development of novel 
treatment. Development of effective treatment also depends on our ability to correctly 
diagnose dementia disorders in vivo. Currently, the clinical diagnosis of dementia 
diseases is sub-optimal, DLB in particular often goes unrecognized8 9. Accurate 
biomarkers and optimal clinical criteria are necessary to improve diagnostic accuracy. 
1.3" Alzheimer`s"disease""
1.3.1(Epidemiology(
AD is the most common cause of dementia, accounting for 60  - 80% of cases10. AD is 
very rare before middle age11. Age, a family history of AD and the apolipoprotein E 
(APOE) "4 allele are the strongest risk factors for sporadic AD12. A population-based 




years, 19.0% at 90 years and finally 25.0% in 100 years olds, which also constitute 
lifetime risk13. More women than men have AD; the main explanation being that more 
women survive to reach the age brackets with high AD prevalence12. Reported age-




The pathology of AD is characterized by extensive synaptic and neuronal loss, and the 
hallmark lesions neurofibrillary tangles and senile plaques14, 15. The neurofibrillary 
tangles are intraneuronal lesions composed mainly of modified tau-protein16. Tau is a 
microtubule-associated protein involved in stabilization of microtubules in neuronal 
axons15. In AD, tau show abnormal phosphorylation of several amino acids, and the 
protein is sequestered in the neurofibrillary tangles16.  
 
Senile plaques are extracellular deposits of beta-amyloid (abeta)-peptides14. Amyloid 
precursor protein is a transmembrane protein that can either be cleaved by the α- and 
the γ-secretases, or by the β secretase and γ-secretase7. The latter pathway leads to  
formation of abeta-peptides of different lengths7. Some abeta peptides, including 
abeta42, are deposited in senile plaques14, abeta42 is more fibrillogenic than the more 
common abeta40-peptide and associated with formation of  abeta-deposits15.  Soluble 
abeta42 oligomers might be toxic17. The morphology of senile plaques is diverse14. A 
subtype with abeta deposits at the center of a cluster of dystrophic neurites that 
sometimes show phospho-tau immunoreactivity is called neuritic plaques14. The 
pathogenesis of AD is still unknown. The so-called amyloid hypothesis stated that 
beta-amyloid dyshomeostatis is the key to initiating AD; this hypothesis is under 
debate with both supporters17 and opponents16. Conformations of tau or abeta42 or 
both might spread in a seeding manner, similar to prion disorders16. Cell and animal 
models, as well as clinical, pathological and genetic studies, suggest that the etiology 
and pathogenesis of sporadic AD is heterogeneous with several pathways to the same 





Six stages of neurofibrillary tangle pathology have been characterized by Braak and 
coworkers; “transentorhinal” (I-II), “limbic ”(III-IV)  and “isocortical”  (V-VI), with a 
mild and severe version of each stage18. Braak and coworkers postulated that the 
neurofibrillary tangle pathology starts in the transentorhinal cortex and then 
successively affects the rest of the limbic system prior to the neocortex. They could 
not find a similarly specific pattern in the development of senile plaques, as the early 
stages of amyloid deposits are heterogeneous18. Amyloid deposits were thus divided 
into only three stages; A, B and C. A was characterized by low densities of amyloid 
deposits in the neocortex, particularly the basal portions of the frontal, temporal and 
occipital lobes. B of medium densities of amyloid plaques in almost all neocortical 
association areas, the hippocampus is only mildly involved, and the transenthorhinal 
cortex might be affected18.  In stage C almost all neocortical areas have high density of 
abeta-deposits, whereas the hippocampal formation, however, has relatively few 
deposits18. Adding to Braak and coworkers staging system for neurofibrillary tangle 
and amyloid-beta pathology, The Consortium to Establish A Registry for Alzheimer’s 
disease (CERAD) proposed a staging system for neuritic plaques in the neocortex, 
from C0: no neuritic plaques, C1: sparse, C2: moderate and C3 frequent plaques19.  
 
Beta-amyloid deposits have no clear correlation with cognitive impairment in AD 
dementia20. The tangle pathology, on the other hand, starts in regions of the brain vital 
for memory function18, correlating to impaired memory being the first cognitive 
function to be affected in typical AD. Tangle pathology is robustly linked to cognition 
and neurodegeneration18, 20, 21.  
 
The senile plaques and neurofibrillary tangles are, per definition, present in all patients 
with AD, however, some degree of plaques and tangles are also found in a majority of 
80 – 90-year-olds, including non-demented subjects coming to autopsy16. One study 
found that the presence of Braak tau stage V in persons with preserved cognition was 
associated with younger age, fewer neocortical neuritic plaques, and no comorbid 




presence of severe neurofibrillary tangle pathology is possible when the individual is 
younger and has no other pathology22.  The same study also showed that when the 
interval between the last assessment of cognitive function and death was three years or 
more the number of people with apparent preserved cognitive function and severe AD 
pathology increased dramatically22, however, when the interval between the last 
assessment and death increases so does the risk for undetected cognitive decline.  
 
The Religious Order Study included Catholic nuns, priests and brothers from the USA 
without dementia, and followed them with annual cognitive assessments until death. 
Approximately 90% of persons meeting clinical AD criteria and 50% of mild 
cognitive impairment (MCI) patients met neuropathologically criteria for AD23. Data 
from this study were combined with results from another study of similar design24. 
Amongst the first 134 persons without dementia or mild cognitive impairment coming 
to autopsy, two had high likelihood and 48 intermediate likelihood of AD according to 
the 1997 National Institute on Aging-Reagan neuropathological AD criteria25(the 
Criteria are described in section 1.5.2 “Neuropathological dementia diagnosis”)24. 
These 50 patients scored significantly lower on episodic memory than the rest of the 
cohort24. In conclusion plaques and tangles occur in normal aging, but more severe AD 




Genetically AD can be divided in two; rare, autosomal dominant forms with high 
penetrance that account for less than 1% of cases, and the multifactorial sporadic form 
with many associated genes26. The most common autosomal dominant forms are 
mutations in the genes for amyloid precursor protein, presenilin 1 and presenilin 226. 
All three genes are closely linked to AD pathogenesis, amyloid precursor protein is the 
precursor to beta-amyloid and the presenilins have been shown to be the catalytic 
subunit of the γ-secretase necessary for abeta formation11. Many of the mutations in 




CSF abeta42/abeta40 ratio27. The autosomal dominant forms often cause early-onset 
AD, although most cases of early-onset AD are sporadic26. 
 
In the sporadic form genome-wide association studies have found multiple risk genes. 
Some related to beta-amyloid processing, but also genes that code for proteins 
involved in the immune system, synaptic functioning, the cytoskeleton, and axonal 
transport, lipid metabolism, regulation of gene expression and posttranslational 
modification26. However, the strongest genetic risk factor in sporadic AD is the ε4 
allele of the APOE-gene26. The brain is the most cholesterol-rich organ in the body28. 
Apolipoprotein E is involved in cholesterol transport, and a regulator of lipoprotein 
metabolism with effects also on inflammation and neuroplasticity28, 29. Research 
suggests a link between Apolipoprotein E and amyloid pathology, Apolipoprotein E 
having been found to have an effect on the clearance of abeta aggregations29. Of the 
three alleles of the APOE gene, the ε3 is most frequent and considered neutral 
regarding risk for AD. ε2 has the lowest frequency and is associated with decreased 
risk for AD and later age at onset28, 29. The ε4 allele is associated with increased 
neuropathological abeta aggregates, and significantly lowers the age of AD onset29. 
AD risk is three times higher in ε4 heterozygotes than non-carriers, and 12-15 times 
higher in homozygotes27, 29.  The allele is carried by > 50 % of AD patients while the 




The neuropathological AD process starts many years before the gradual onset of 
cognitive symptom. In addition to cognitive decline, the diagnosis of dementia, 
according to the ICD-10, and major neurocognitive disorder, the Diagnostic and 
Statistical Manual of Mental Disorders (DSM) 5 equivalent, also requires impairment 
of functions of daily living. This requirement that the cognitive decline impairs 
function of daily living is of vital clinical importance, but at the same time also 




might vary from a demanding job to a sedentary retired life. Studying early disease 
and addressing patients with cognitive impairment that falls short of dementia has 
paved the way for the construct of “mild cognitive impairment”, MCI. MCI can be 
defined as either reports of cognitive impairment from patient or carer that can be 
verified on cognitive tests or evidence of cognitive decline from previous level of 
functioning in persons that are independent in activities of daily living30, however, 
several other definitions exist. The MCI population is heterogeneous1, and from MCI 
there are three different trajectories; some remain stable, some improve and some 
develop dementia. The risk of developing dementia is higher in a person diagnosed 
with MCI compared to the general population1. MCI patients with prodromal AD 
typically have impairment of episodic memory31. The National Institute on Aging and 
the Alzheimer´s Association have jointly published criteria for MCI due to AD, 
including research criteria where AD biomarkers are used for the diagnosis of MCI 
due to AD (for more information on AD biomarkers see section 1.3.5)31. Based on the 
biomarker supported criteria, 46% of MCI patients had a high likelihood of prodromal 
AD (both beta-amyloid and neuronal injury biomarker positive) with a three year 
conversion rate to AD of 59%32. In comparison, 22% of individuals with a positive 
beta-amyloid but negative neuronal injury biomarker, and 24% of individuals with a 
negative beta-amyloid but positive neuronal injury biomarker progressed to AD over 
three years, and only 5% of individuals with low likelihood of MCI due to AD 
(negative abeta42 and neuronal injury biomarkers) developed AD32.   
 
The typical presentation of AD is the amnestic syndrome, with impairment on delayed 
recall tests not significantly improved with cuing33. Impairment of executive functions, 
such as the ability to plan and execute goal-directed behavior is also common11. 
Approximately 6 – 14 % of cases have an atypical presentation, with relatively 
preserved memory at disease debut33. Atypical variants usually have an earlier onset 
than the amnestic variant33. It has been suggested that atypical variants can be divided 
into specific subtypes. A logopenic variant with early impairment of retrieval of single 
words and repetition of sentences33. A frontal variant with early and predominant 




testing33. A posterior variant, which is divided into an occipitotemporal and a 
biparietal variant respectively, with the occipitotemporal variant dominated by 
impairment of visuoperceptive functions such as identification of objects, faces, and 
symbols and the biparietal of early impairment of visuospatial function, limb apraxia 
or neglect33.  
 
After the emergence of the first symptoms, the neurodegeneration progresses, leading 
to further deterioration of cognitive and ADL functions, leading to loss of independent 
functioning. The patients often first require assistance at home, and subsequently, 
nursing home placement is often needed. In very severe AD the patient can no longer 
walk, talk or eat independently. The time to progression from diagnosis of AD to 
severe dementia is highly heterogeneous. A population-based incidence study found 
that 30 - 58% of AD patients progressed less than one point per year on the Mini-
Mental State Evaluation (MMSE) even 5-7 years after the onset of dementia, women 
and younger patients progressed faster34. Reported time from diagnosis to death and 
loss of life years vary considerably between studies35. A German incidence study 
found a median survival of 3.2 years after AD diagnosis in a population of persons > 
75 years of age, mean  age of onset was 85 years36. A population-based study of 
incident dementia in England and Wales found median survival of 4.5 years after 
estimated dementia onset, survival varied from median 10.7 years in those <70 years 
to 3.8 in individuals > 9037. 
NonTcognitive(symptoms(
Non-cognitive symptoms such as motor-, neuropsychiatric- and behavioral symptoms 
are common in the course of AD38. 50% of all-cause MCI and 80% of all cause-
dementia experience at least one neuropsychiatric symptom from the onset of 
cognitive impairment39. Neuropsychiatric symptoms include apathy, depressive 
symptoms, anxiety, irritability and aggression, non-aggressive agitation, 
hallucinations, delusions, misidentification, apathy, sleep-problems, wandering and 
elation40. A systematic review found a higher prevalence of these symptoms in studies 
of patients with moderate to moderately severe dementia than in studies including 




neuropsychiatric symptoms over time is important for the impact on patients and 
carers. Hyperactivity and apathy have both high incidence and persistentence, anxiety 
and depression have moderate incidence and low persistence, while psychotic 
symptoms have moderate to low incidence and low persistence40.  
 
Neuropsychiatric and behavioral symptoms are associated with increased caregiver 
burden, psychological distress, and depression41.  These symptoms might also increase 
the risk of nursing home admission41 and predict the development of dementia from 
mild cognitive impairment42. They are also associated with faster progression to severe 
AD43 and shorter survival43, 44. Although the field has received increased research 
interest in the later years, the pathology underlying the highly variable development of 
neuropsychiatric symptoms in individuals with AD is largely unknown45-55. 
 
1.3.5(Biomarkers((
The World Federation of Societies on Biological Psychiatry´s Task Force on 
Biological Markers summarized previously published criteria for diagnostic 
biomarkers in neurodegenerative dementias in general and AD in particular. A marker 
should be; 
 
•" linked to fundamental features of the neuropathology, 
•" validated in neuropathologically confirmed cases, 
•" able to detect the disease early in its course and distinguish it from other 
dementias,   
•" non-invasive, simple to use and inexpensive,  
•" not influenced by symptomatic drug treatment7.  
 
CSF(and(bloodTbased(biomarkers(
The most commonly used and promising AD biomarker modalities will be described 
in brief here. The abeta42 peptide and the proteins t-tau and p-tau, are the most 




181, p-tau181. In AD abeta42 is decreased and t-tau and p-tau increased compared to 
healthy controls56. The CSF markers are closely linked to AD pathogenesis. The 
abeta42 decrease likely represents its deposition in amyloid plaques, t-tau is a marker 
of the intensity of neurodegeneration and p-tau is the modified tau form sequestered in 
neurofibrillary tangles56. The markers have been reported to identify AD at the mild 
cognitive impairment stage with sensitivities and specificities around 85-90%11. As 
mentioned previously, AD neuropathological lesions can also be found in people 
without clinical AD dementia at the time of death, and multiple pathologies are 
commonly present in dementia patients. Thus biomarkers that detect neuropathological 
AD lesions will never predict clinical AD dementia perfectly. However, a normal 
biomarker profile has been shown to have high negative predictive value of AD 
development in MCI11. Blood-based biomarkers would be attractive but have proved 
difficult to find. No blood-based markers are included in current research criteria for 
AD33, 57.  
ImagingT(and(nuclear(medicine(biomarkers((
Atrophy of the medial temporal lobe on MRI is an AD biomarker, hippocampal 
volumetry might be superior to visual rating11. Sensitivity and specificity for medial 
temporal lobe atrophy on MRI across assessment methods is 75% and 81% for AD 
dementia vs normal controls, and 62% and 73% respectively for MCI progressing to 
AD vs non-progressive MCI58.  
 
Both 18F-fluorodeoxyglucose (FDG) PET and PET with tracers that bind to core AD 
pathology are used. The FDG PET measures glucose uptake by glial cells and neurons, 
with the finding of a specific pattern of hypometabolism in the temporoparietal and 
posterior cingulate regions being suggestive for AD11. Temporoparietal 
hypometabolism has a sensitivity of 86% and specificity of 84% for AD dementia vs 
controls and sensitivity of 76% and a specificity of 74% for MCI progressing to AD vs 
non-progressive MCI58. Specific for AD neuropathological lesions, amyloid tracers 
were first developed more than a decade ago, while tau tracers are a more recent 
addition20. The 11C-PiB (PiB) tracer binds to abeta in plaques and other lesions, and 




Increased PiB binding correlates strongly with decreased abeta42 in CSF20. As 11C-PiB 
has a 20-minute half-life, use is limited to centers with a cyclotron, and this has 
inspired the development of tracers labeled with fluorine-18 (18F) which has 110 
minutes half-life20. Different 18F tracers appear to replicate the PiB results20.  
 
Sensitivity for amyloid imaging with PET is 88% for AD against healthy aging, and 
82% for MCI progressing to AD vs stable MCI, with specificities of 85% and 56% 
respectively58. The low specificity for progressive vs non-progressive MCI might in 
part be due to amyloid accumulations preceding dementia by many years. Amyloid 
deposits have been found in cognitively intact individuals, perhaps representing pre-
clinical disease20. Currently this is a limitation for the use of amyloid imaging as an 
AD biomarker.   
 
The sequential spreading of tau- and neurofibrillary tangle pathology18 and its 
correlation with cognitive impairment and neurodegeneration14, 20 make tracers that 
bind to this pathology attractive as AD markers. Several tracers have been developed, 
such as THK5317, THK5351, AV-1451 and PBB359. Tau tracer could be used for 
diagnostic purposes, as well as  staging and monitoring of disease progression as it 
provides the opportunity to follow the pattern of tau depositions in vivo59. However, 
much research is still needed to ascertain the binding properties of the tracers to 





The ICD-10 does not include criteria for DLB, and in the DSM DLB was first 
introduced with the publication of DSM 5 in 2013 as Major and Minor Neurocognitive 
disorder with Lewy bodies. In research, the criteria published by the DLB consortium 




and have since been revised twice60-62, for details see table 1. The central feature of 
dementia has been consistent across revisions, as have the core features fluctuating 
cognition, visual hallucinations and parkinsonism. However, the required severity of 
parkinsonism has been revised. In the 1996 criteria parkinsonism was described as 
typically mild60, in the 2005 as equally severe to age-matched PD patients61 and in the 
2017 criteria, only one of the cardinal features of PD is necessary to fulfill the 
parkinsonism trait62.  
 
The 2005 criteria added “suggestive features”; REM-sleep behavior disorder (RBD), 
severe neuroleptic sensitivity and evidence of reduced dopamine uptake in the basal 
ganglia demonstrated by SPECT or PET, with one core and one suggestive feature 
sufficient for a probable DLB diagnosis61. In 2017 the “suggestive features” category 
was removed, but replaced by “indicative” and “supportive biomarker” categories. 
Reduced dopamine uptake in the basal ganglia by PET or SPECT (dopamine 
transporter imaging), abnormal MIBG myocardial scintigraphy and polysomnography 
confirming REM sleep without atonia were now defined as an indicative biomarkers 
and RBD included as a core feature62. One core feature and one indicative biomarker 
are now sufficient for a diagnosis of probable DLB. All three sets of criteria have 
addressed the distinction between DLB and PDD. Dementia developed in established 
PD should be labeled PDD. Dementia with subsequent parkinsonism and dementia and 
parkinsonism emerging concomitantly should be labeled DLB. In research settings the 
one-year-rule is recommended, if dementia develops within a year after onset of 












Abbreviations: RBD: REM sleep behavior disorder. No temporal lobe atrophy: “relative preservation of medial temporal 
lobe structures on CT/MRI scan”62, Positive perfusion SPECT/PET: “generalized low uptake on SPECT/PET 
perfusion/metabolism scan with reduced occipital activity ± the cingulate island sign”62. Typical EEG: 2005: ”prominent 
slow wave activity on EEG with temporal lobe transient sharp waves”61. 2017: prominent posterior slow-wave activity on 
EEG with periodic fluctuations  in the pre-alpha/theta range62. Positive DAT imaging: “Reduced dopamine uptake in basal 




Although clinically defined as a movement disorder, the cognitive impairment in PD is 
common and developing gradually. Motor impairment also influences function, thus 
pinpointing the time an individual reaches dementia can be difficult. The ICD-10 
defines PDD simply as “dementia developing in the course of established Parkinson 
disease. No particular distinguishing clinical features have yet been demonstrated”4. 
The International Parkinson and Movement Disorder Society has published PDD 




•" Dementia, defined similarly to the ICD-10 dementia criteria, but without the 
specification that memory must be affected. 
•" A cognitive profile with impairment of at least two of the following domains; 
executive functions, visuospatial functions, attention, and free recall – which 
usually improve with cueing. 
•" Behavioural symptoms such as hallucinations, apathy, delusions, depression, 
anxiety, and daytime hypersomnolence support the diagnosis but is not 
mandatory.  
•" Other pathology associated with cognitive impairment, but judged not to be the 
cause of dementia, should not be present, for instance, significant vascular 
lesions. The time between the onset of motor and cognitive symptoms should 
be known. 
•" There should not be sufficient vascular pathology to fulfil criteria for vascular 





The exact incidence and prevalence of DLB are unknown for several reasons. 
Population-based incidence studies that break dementia into different diagnosis are 
few, as they are expensive and difficult to organize. The 1996, 2005 and 2017 DLB 
criteria might not identify the same patients, and DLB is probably underdiagnosed64.  
 
A systematic review found that in the studies published after 2005, the prevalence of 
DLB in the population > 65 years was 0 – 1.2%, and between 0 – 9.7% of dementia 
cases had DLB64. Average incidence was found to be 0.87 cases / 1000 person-years in 
the population > 6564. This estimate was based on three studies; one applied the 1996 
criteria and reported an incidence of 0.57 /1000 person-years, and two studies using 
the 2005 criteria found 1.12 and 1.40 /1000 person-years respectively64. In secondary 




dementia with DLB, was 7.5%64. Prevalence varied greatly from 2.2% - 24.7% of 
cases, again the studies using the 2005 criteria reported the highest prevalence64. There 
were no clear differences in gender, but a trend towards positive correlation between 
age and DLB prevalence64.   
PDD(
PD prevalence increases gradually with age, from 0.11% in individuals aged 50 to 59 
years, to 0.43 in individuals 60 -69, 1.1% in individuals aged 70- 70 years and 1.9% in 
individuals > 80 years65. PD incidence is higher in men than in women66. Cognitive 
impairment is common in PD, at time of diagnosis prior to treatment approximately 1 
in 5 patients has mild cognitive impairment67. The point prevalence of dementia in PD 
is approximately 30%68 and increases with disease duration. In an incidence cohort, 
the prevalence of dementia was 46% in survivors after 10 years69. A longitudinal study 
found that 75% of PD patients were diagnosed with dementia prior to death, while 9% 
died early from unrelated causes and another 11% died more than one year after their 
last cognitive assessment70. The same study found a cumulative prevalence of 
dementia of 83% in the few who survived 20 years after PD diagnosis70.  
 
A review of 18 longitudinal studies found that the three most influential factors for 
cognitive impairment and dementia in PD are hallucinations, older age, and severity of 
PD symptoms71. Impaired speech, PD onset at a higher age, the severity of 
bradykinesia and axial impairment (i.e. impairment of gait and postural instability), 
shorter education, depression, and male gender are also risk factors71. In addition to 
this, RBD72, orthostatic hypotension72, mild cognitive impairment72, 73 and reduced 




The hallmark features of LBD are Lewy bodies in the cell soma and Lewy neurites in 
neuronal cell processes, and misfolded α-synuclein is the main constituent of both16. α-




outside the central nervous system75. The function has yet to be thoroughly described, 
but several reports point to a role in synaptic vesicular transport75. There is no 




In addition to Lewy body diseases DLB and PD, multiple system atrophy (MSA) is 
also associated with α-synuclein aggregations. In MSA these lesions occur 
predominantly in oligodendroglia and Schwann cells, as opposed to neurons like Lewy 
bodies and neurites76. The Lewy body pathology is associated with neuronal loss, but 
whether the Lewy bodies and Lewy neurites are neurotoxic is unknown77. The toxic 
agent might be α-synuclein oligomers (i.e. several α-synuclein proteins bound to each 
other), α-synuclein fibrils (i.e. much larger structured aggregates)75, 76 or another 
substance. The observation that embryonal neural tissues transplanted into the striatum 
of PD patients developed α-synuclein pathology lead to a theory that α-synculein is a 
prion-like protein75, 76. Mitochondrial dysfunction seems to play a key role in PD78. 
Concomitant amyloid plaques and neurofibrillary tangles are common in LBD5, 79, 





The 1996 criteria by the DLB consortium divided neuropathological Lewy body 
pathology into brainstem predominant, limbic (transitional) and neocortical, based on 
semiquantitative assessments of distribution and frequency60. These criteria required 
only the presence of Lewy bodies somewhere in the brain for a patient with dementia 
to be classified as DLB, regardless of the presence of other pathology60. Thus up to 
60% of AD patients would be neuropathologically classified as DLB61. The 2005 
criteria addressed this issue by including likelihoods of the clinical DLB syndrome 
with different combinations of Lewy body and AD pathology, combinations could 
have “low”, “intermediate” or “high” likelihoods of clinical DLB61.  
 
The criteria from 2017 are presented in table 2, reproduced from the original 
publication. In the 2017 criteria62, the neuropathological AD criteria were updated to 
the most recent National Institute on Aging-Alzheimer´s Association guidelines80 and 
amygdala predominant and olfactory bulb only stages of DLB pathology were added. 
Both are considered low likelihood for the DLB syndrome, but possibly represent a 
prodromal stage of disease62. The new criteria also include a sub-classification with 








As evident from the table, the likelihood of a clinical DLB syndrome increases with 
limbic and ultimately neocortical Lewy related pathology, and concomitant AD 
pathology decreases the likelihood for a DLB phenotype.  
PDD(
At its core, Parkinson`s disease is a clinical syndrome with degeneration of 
dopaminergic neurons in the substantia nigra pars compacta. The gold standard of 
diagnosis has been neuropathological verification of this degeneration and the 
presence of Lewy related pathology81. Braak and coworkers have proposed a 6 step 
caudal-to-rostral spreading of Lewy related pathology in PD; stage 1 where the 
pathology starts in medulla oblongata and frequently also the anterior olfactory 
nucleus, stage 2 where pathology spreads in the medulla oblongata and starts to affect 
pontine structures, stage 3 with involvement of mesencephalon including substantia 
nigra pars compacta, stage 4 were pathology involves more limbic structures and 
temporal cortex, and stage 5 and 6 where neocortical regions are involved82. This 
theory could explain the temporal development of clinical PD; the first symptoms are 




could be explained by stage 1 and 2. The subsequent development of the motor 
symptoms corresponds to stage 3. Stages 4 – 6 would be consistent with the many 
non-motor symptoms of advanced PD, including dementia82.  
 
Not all autopsy studies support this theory, however the correlation between the 
severity of cortical Lewy body pathology and dementia is strong81. It is important to  
remember that Lewy body pathology is not the sole underlying pathology of cognitive 
impairment in PD. Neurofibrillary tangles and amyloid plaques are common, and 
severe concomitant AD pathology is strongly associated with dementia5, 79, 84, 85. A 
higher number of cerebrovascular lesions have been found in PDD patients compared 
to PD86. DLB and PDD cannot be separated neuropathologically. Thus, in summary, 
cortical Lewy body pathology is strongly linked to cognitive impairment. Comorbid 
AD pathology is common and likely affects the clinical presentation – both the 




Increased risk for DLB and visual hallucinations have been found in siblings of DLB 
patients compared to siblings of AD patients, odds ratio (OR) 2.3 and 2.3 
respectively87. The largest genome-wide association study performed to date point to 
three different loci being strongly associated with DLB risk88. First, like in AD, the 
APOE-gene is involved, and carriers of the APOE ε4 allele were reported to have OR 
of 2.4 compared to non-carriers88. Interestingly carriers of an APOE ε2 allele were by 
another study reported to have decreased risk for DLB, with an OR of 0.489. The 
second loci found to have a significant association with DLB risk is the gene encoding 
glucocerebrosidase (GBA), a lysosomal enzyme which may influence α-synuclein 
processing90. The effect of this loci was an OR of 2.6 for DLB compared to controls88. 
The third loci found to be strongly associated with DLB risk was the SNCA gene 
coding for α-synuclein, with an OR of 0.7, translating to a reduced risk of DLB of 




monogenetic forms of neurodegenerative diseases have been found in 4.4% of patients 
with DLB91. The hereditability of DLB was estimated to 36%88.   
PDD(
Approximately 15 % of PD patients have a family member with PD, and 5-10% of 
cases are caused by either autosomal dominant or autosomal recessive mutations in 
single genes92. 10 genes with autosomal dominant mutations have been identified, 
including in the SNCA and leucine rich repeat kinase 2 (LRRK2 )genes, mutations in 
the LRRK2 is the most common genetic cause of PD92. The LRRK2 protein is 
involved in the cytoskeleton, vesicular transport, protein synthesis, and lysosomal 
systems92. Mutations may lead to degeneration and death of dopaminergic neurons92. 
The genes that code for proteins DJ-1 and parkin are among the 9 autosomal recessive 
genes identified to date92. Both proteins are vital for mitochondrial function, and 
mutations cause early onset PD81, 92. Genetic risk factors for PD include mutations in 
the GBA, LRRK2 and SCNA genes, and in the MAPT gene coding for the protein tau 
(see the AD section)92. Interestingly, genetic risk factors for cognitive impairmentand 
dementia in PD have been discovered, including the APOE "4 allele93, 94, and specific 




Interviews with LBD patients at the time of diagnosis indicate that the first symptoms 
10 – 15 years prior to diagnosis are non-cognitive96; decreased sense of smell, RBD, 
constipation, dizziness while standing, urinary incontinence and increased salivation 
and sweating96. Subsequently, some experience delirium, depression and psychosis, 
and later cognitive impairment of a non-amnestic subtype, visual hallucinations, 
illusions, misconceptions, and parkinsonism occur96. Whether prodromal DLB and PD 
can be differentiated from each other is a priority but not yet known96. Although this 
approach is susceptible to recall bias, and many of these symptoms common in normal 
aging, these findings suggest that prodromal DLB might be heterogeneous with both 





Idiopathic RBD is an important prodrome for LBD97. After a follow-up of mean 3.6 
years, 17 of 76 idiopathic RBD patients developed PD, 15 DLB, and two MSA98. 
Although most MCI who progress to dementia have AD, some will also develop DLB. 
MCI patients who later developed DLB (DLB-MCI) scored worse on visuospatial 
function- and letter fluency tests compared to stable MCI and MCI patients who 
developed AD (MCI-AD), however scored better on tests of episodic memory than 
MCI-AD99. The MCI-DLB group had higher UPDRS-III scores and more fluctuating 
cognition and RBD than the stable MCI and MCI-AD patients99.  
Cognitive(profiles(
DLB patients on average have a profile of cognitive impairment dominated by 
impaired attention, executive- and visuospatial functions rather than impairment of 
memory and naming62, 100. In the Demvest-cohort mild DLB patients scored 
significantly worse than mild AD patients on visuoconstruction (MMSE pentagon test) 
and all tests involving attention and executive functions, with the exception of verbal 
fluency100. The AD patients scored significantly lower on memory tests, both delayed 
recall and recognition100. Visuoperception was similar in both groups but was assessed 
with a test which required patients to name objects and animals101. Naming can be 
more difficult for AD patients resulting  in findings that are difficult to interpret100. 
The cognitive profile was able to correctly classify 79.1% of patients, however, 32% 
of the DLB patients were misclassified100, thus there is a significant overlap between 
cognitive profiles in early AD and DLB.  
 
The cognitive profile in PDD includes impairment of executive functions, attention, 
and visuospatial functions, but not always delayed recall at dementia onset63. Whilst 
few studies have compared DLB and PDD with equal severity of dementia, some have 
found DLB patients to have more impaired attention, others found no difference102. 
Both DLB and PDD have been found to have a higher likelihood of a “subcortical” 
cognitive profile, i.e. impairment of initiation, construction and attention vs the 
“cortical” profile common in AD, with severe impairment of delayed memory, but 






The main clinical features that characterize DLB and separate it from other dementias 
are increased prevalence of cognitive fluctuations, visual hallucinations, parkinsonism, 
and RBD compared to other dementing disorders. Fluctuations in cognitive function 
and attention are perhaps the core DLB feature that is most difficult to assess 
clinically. Fluctuations can be rapid, lasting minutes to hours or slower – with weekly 
to monthly variations60. They can be experienced by carers as periods of daytime 
drowsiness, episodes of disorganized speech or staring into space62 or as the patient 
being “switched off”60.  Sometimes fluctuations may be as extreme as transient 
episodes of non-responsiveness and therefore difficult to differentiate from syncope62.  
 
However, fluctuations are not specific for DLB. Fluctuations in both motor- and non-
motor symptoms are also common in advanced PD and may be related to long-term 
dopaminergic treatment81. One study which tested alertness and cognition during 48 
hours of observation found greater fluctuations of cognition in DLB compared to PD 
patients without dementia, but no difference in fluctuations in alertness104. Fluctuations 
also become increasingly common in more advanced dementia of other etiologies105 
and are thus less specific for DLB in moderate and severe dementia8. Repeated tests of 
cognition and attention, computerized or manually administered can be used to detect 
fluctuations104, 106 but structured scales administered to carers are the most used tools 
for assessment107, 108. The use of one such measure of fluctuations in the diagnostic 
process is advised by the DLB consortium62.  
Visual"hallucinations"
Early visual hallucinations in the course of dementia should lead to a suspicion of 
DLB; visual hallucinations are reported in 35% - 85% of autopsy-confirmed cases109. 
Hallucinations are typically well-formed; patients typically see people or animals62. 
Some, but not all, have preserved insight that these experiences are illusions, and the 
emotional content of the hallucinations is variable62. However, visual hallucinations 




visual hallucinations, which are usually simple, but complex hallucinations may also 
occur110. Visual hallucinations are also common in AD, but usually present in the more 
advanced stages compared with DLB109. In an autopsy verified study most visual 
hallucinations in DLB occurred during the first 5 years after estimated dementia 
onset109. The presence of visual hallucinations during in this period were associated 
with high likelihood of autopsy verified DLB vs AD109. Hallucinations in other 
modalities also occur in DLB, but less frequently62.  
 
Both illusions, hallucinations and delusions occur in PD, with the more severe forms 
being referred to as “PD psychosis”. Typically the onset is insidious, but with 
increasing severity of PD, fully formed visual hallucinations can evolve111. Insight is 
usually preserved in early stages but often diminishes with disease progression. Loss 
of insight is associated with impaired cognition111. Delusions and non-visual 
hallucinations, such as tactile, olfactory and auditory hallucinations, might also 
develop as PD progresses111. PD psychosis is common, in very early PD 42% of 
patients reported minor phenomena, and overall 22 – 38% of PD patients have 
complex visual hallucinations112, 113. Visual hallucinations are linked to limbic Lewy 
body pathology, but reports have also implicated tau and amyloid pathology in the 
frontal, parietal and hippocampal areas and the cholinergic system111. Dopaminergic 
treatment increases the risk of psychosis, although to what extent, and the exact nature 
of the effect is still controversial111.  
Parkinsonism"in"DLB"
Spontaneous features of parkinsonism are common in DLB62. One study found 
parkinsonism within 3 years of disease onset in 82% of autopsy verified DLB114. 
Parkinsonism in DLB has been characterized more by postural instability, gait 
difficulty and facial immobilization and less rest tremor than PD61. The 2017 revision 
of the DLB criteria acknowledged that parkinsonism in many DLB patients falls short 
of the International Parkinson Disease and Movement Disorder Society PD criteria, 
i.e. bradykinesia in addition to rest tremor, rigidity or both115. Thus the 2017 criteria 
require only one of the cardinal PD criteria to fulfill this criterion62. However, the need 




neurological examination tests due to cognitive impairment or comorbid conditions is 
stressed62.  
REM"sleep"behavior"disorder"
The inclusion of RBD as a core criterion in DLB has been shown to increase the 
diagnostic accuracy of clinical DLB diagnosis in autopsy verified cases116. 
Polysomnography is used to detect RBD, this is, however, costly and subjects must be 
able to and willing to cooperate117. The Mayo Sleep Questionnaire, where the bed 
partner is asked about dream enactment behavior, has in some studies been used 
instead of polysomnography, but requires a bed partner or someone who regularly sees 
the patient sleep117. Polysomnography is needed when there is doubt as to whether the 
sleep disturbance is RBD or other conditions common in old age, such as obstructive 
sleep apnea, confusional awakening, and periodic leg movement62.  
Other"symptoms"
Autonomic dysfunction in LBD leads to symptoms such as constipation, orthostatic 
hypotension, and urinary incontinence62, 81. Patients with DLB often have adverse 
reactions to antipsychotic agents, from mild symptoms such as drowsiness to 
irreversible cognitive decline, worsening of parkinsonism, and full-blown malignant 
neuroleptic malignant syndrome118. In PD, antipsychotics other than clozapine, 
quetiapine, and pimavanserin frequently worsen parkinsonism81. Excessive daytime 
sleepiness, increased risk for falls, anxiety, depression, apathy, and hyposmia have 
also been found to be associated with LBD62, 83, 119.  
Prognosis(
Several previous studies have found different trajectories after diagnosis in AD and 
DLB120, 121. The largest study published to date with more than 800 participants found 
a faster annual decline in MMSE scores in DLB (2.1) compared AD (1.6) and PDD 
(1.8) from mild dementia, after adjusting for MMSE at inclusion120. In the Demvest 
study, DLB patients had more rapid cognitive decline than the AD patients, with DLB 
patients progressing to severe dementia 5 months earlier than AD patients121. Contrary 




between AD and DLB122. However, patients with mixed DLB and AD pathology may 
have the most rapid decline123.  
 
Admission to residential care is an important milestone of disease progression; an 
indicator for large care needs and associated with high costs. Known triggers for 
nursing home placement in dementia include neuropsychiatric symptoms such as 
psychosis and aggression, as well as motor impairment leading to greater disability123. 
Thus DLB patients might require early nursing home placement due to the complex 
clinical profile including neuropsychiatric symptoms123. In the Demvest study, median 
time from mild dementia to nursing home placement was almost two years shorter in 
DLB than for the AD patients124. Others studies, however, have failed to find a 
difference123. Three of four studies that compared financial burdens in AD and DLB 
found higher costs in DLB123. Comorbid AD pathology, the APOE ε4 allele, gait 
abnormalities, fluctuating cognition, and hallucinations are associated with shorter 
survival in DLB123. A study with patients diagnosed in clinical practice in the United 
Kingdom found a median survival after diagnosis of 3.7 years in DLB compared to 7.0 
years in the AD group125, similar differences was found in the Demvest cohort126. 
These findings of shorter survival in DLB compared to AD are backed by a majority 
of the relatively few studies published127.   
 
MCI is a prodrome for dementia in PD. However, as in the normal population, MCI 
may revert to normal cognition, thus the presence of MCI does not necessarily herald 
dementia112. It has been suggested that MCI in PD is in fact two different syndromes; 
one fronto—subcortical syndrome with executive deficits associated with loss of 
dopaminergic innervation to the striatum, and a posterior cortical syndrome with 
impairment of visuospatial functions and memory associated with Lewy body 
pathology and cholinergic deficits94. Research suggests that the cortical posterior 
syndrome is a stronger risk factor for dementia112.  
 
The cumulative prevalence of dementia is very high in PD – but the timing from PD 




patients experience a period with very little or no cognitive decline, followed by an 
inclination point leading to more rapid cognitive decline128. Whilst the time to this 
inclination point is highly variable, the prognosis after the onset of dementia is more 
homogenous128. In addition to dementia, visual hallucinations, regular falls, and need 
for residential care and death are important milestones in PD. Time from diagnosis to 
the first milestone is significantly longer in younger patients129. After the patient 




The common occurrence of AD pathology in DLB also affects the interpretation of the 
CSF AD biomarkers abeta42, t-tau, and p-tau. A CSF AD profile has been found in 
25% of DLB patients130, and the presence of reduced levels of abeta42 are associated 
with more rapid cognitive decline in clinically diagnosed DLB patients131. As 
mentioned previously, reduced abeta42 in early PD has consistently been shown to 
predict more rapid cognitive decline in early PD73, 74, 132.  
 
Biomarkers that could reliably detect !-synuclein pathology would be very attractive 
in LBD. Commercial assays for measurement of !-synuclein have been available for 
some years. The total !-synuclein concentration is decreased by approximately 10 – 
15% in CSF in early, untreated PD patients compared to controls, it is also decreased 
in DLB and PD compared to AD, however with significant overlap between patient 
groups7, 133, 134. It has been suggested that specific !-synuclein species, such as 
oligomers or phosphorylated !-synuclein might have a closer relationship to the 
pathology and prove to be superior biomarkers7. Differences in oligomeric !-synuclein 
in PDD compared to PD have been suggested135. However, these are still new concepts 






The dopaminergic neurons in substantia nigra pars compacta that degenerate in LBD 
project to the striatum81. The loss of dopaminergic transmission to the striatum can be 
assessed with dopaminergic imaging, most commonly using ligands that bind to 
presynaptic dopamine transporters81. The amount of binding is assessed with SPECT 
or PET, DAT is now a well-established PD and DLB biomarker62, 81. In addition to 
LBD, DAT imaging can be abnormal in MSA, progressive supranuclear palsy (PSP), 
and FTD as DAT is not a synucleinopathy marker, and will therefore be abnormal if 
there is another pathology in the striatum62, 136. Against AD, 123I-FP-CIT DAT imaging 
(commercially DaTSCAN) had a sensitivity of 80% and specificity of 92% for DLB in 
autopsy-verified cases, thus performing better than clinical diagnosis in the same 
study136. It is important to point out that a normal DAT imaging does not rule out 
DLB. Normal DAT imaging could be explained the location of pathology at 
presentation, some patients likely have  predominantly limbic and neocortical affection 
with little striatal neuronal loss136.  In addition, a diffuse loss of dopamine across the 




18F-FDG PET traces glucose metabolism in different regions of the brain. Both AD 
and DLB patients have reduced uptake in temporal and parietal lobes137. Compared to 
individuals with AD, DLB patients generally have a more extensive occipital loss, 
while AD patients have reduced uptake in the medial temporal lobe137. In clinically 




and specificity of 74% and 70% respectively for separating AD from DLB patients137. 
The “cingulate island sign”, that is relative preservation of metabolism in mid-or 
posterior cingulate gurus, has been shown to differentiate DLB from AD62, 137. DLB 
and PDD patients have similar patterns of glucose metabolic changes112. Amyloid 
imaging (see section 1.3.5) show that more DLB than PDD patients have equally 
severe beta-amyloid deposits as AD patients (assessed with PiB PET)138. In DLB 
deposits are seen in > 50% of cases, limiting its usefulness as a biomarker separating 
DLB and AD138. Higher PIB-retention were found to correlate with progression from 
PD with normal cognition to PD with mild cognitive impairment (PD-MCI), and 
conversion from PD-MCI to PDD139.  
 
The autonomic deinnervation in DLB can be visualized using 123Iodine-MIBG 
myocardial scintigraphy. Comorbid conditions and medication use must be taken into 
consideration while interpreting results62. Polysomnographic verification of RBD in a 
patient with dementia is highly indicative of α-synuclein pathology, which is useful 
against AD but cannot differentiate between PD, MSA, and DLB140. Medial temporal 
lobe atrophy is another feature that can be used in differentiating between AD and 
DLB, as the medial temporal lobe is relatively preserved in DLB62. A visual rating 
scale of the medial temporal lobe on MRI had a sensitivity of 64% and specificity of 
68% for DLB vs AD in autopsy verified cases141. However, combinations of AD and 
Lewy body pathology are common and medial temporal lobe atrophy cannot rule out 
Lewy body pathology62.  
 
Structural MRI findings associated with cognitive impairment in PD include 
hippocampal atrophy, and cortical volume loss in posterior, parietal and frontal 
regions112. Patterns of cortical thinning can predict conversion from PD to PD-MCI, 
and with the development of PDD the cortical thinning is more severe112. Specific 
EEG patterns have also been suggested as LBD biomarkers. Studies have reported an 
association with cognitive impairment in PD135, ability to predict progression to DLB 
in MCI135, and differentiate DLB from AD62, as well as a correlation with clinically 






In addition to fulfilling the criteria for the dementia syndrome (see section 1.1), the 
relevant differential diagnosis must be considered and the specific dementia disease 
must be ascertained. Information from a carer/person with specific knowledge of the 
patient is necessary for assessment of the patient’s level of functioning and the 
presence of neuropsychiatric symptoms, changes in emotional control, social behavior, 
and motivation, as the patient is often not a reliable assessor of his/her own function 
due to reduced insight and awareness as a consequence of the disease itself. 
 
Cognitive testing must be broad enough to cover relevant domains, as well as 
standardized. Sensory impairment such as impaired vision or hearing must be 
corrected in the best possible manner, striving to make test results as representative as 
possible for the patient’s current level of cognition. Importantly, all conditions that 
impair cognition could mimic dementia and thus careful history taking, including 
comorbid conditions and current medication is necessary. A general clinical and 
neurological examination should be performed. One important differential diagnosis 
that must be excluded is depression, which is common and can affect both cognitive 
function and activities of daily living. Structural intracranial pathology such as 
subdural hematoma, brain tumors, and normal pressure hydrocephalus must also be 
considered, and preferable MRI or alternatively a CT scan should thus be included. 
Structural imaging is also necessary to diagnose vascular dementia. Routine blood 
tests are also performed to exclude other conditions that could mimic dementia. 
Dementia differential diagnosis has traditionally been based on solely clinical criteria. 
However, newer research criteria include biomarkers33, 57, 62, and biomarkers such as 
the volume of the hippocampal region and CSF AD markers t-tau, p-tau181 and 
abeta42, DAT imaging, and FDG and amyloid PET are routinely included in clinical 
workups1. The use of CSF biomarkers varies considerably globally, in the Netherlands 
and Sweden 40% of newly diagnosed dementia patients had a lumbar puncture1. The 




patients < 65 years, and the European Federation of Neurological Societies 
recommends that markers analysis in patients with an atypical AD presentation1. Both 
CSF markers and amyloid PET are also used to differentiate prodromal AD from the 
heterogenous MCI group1.  
 
1.5.2(Neuropathological(dementia(diagnosis(
Neuropathological dementia diagnosis requires macro- but particularly microscopic 
assessment of brain tissue. All the pathologies must be recorded and in the end, a 
conclusion is drawn about which pathology is responsible for the dementia syndrome. 
The emergence of immunohistochemistry has been a major advantage for the detection 
of the different types of pathology present in dementia. As an aid in this process and to 
secure comparability between centres, standardized protocols have been developed for 
brain dissection, macroscopic description, which regions to analyse, and for tissue 
processing and staining14, 142-145.  
 
The neurofibrillary tangles stages from I-VI introduced by Braak and Braak in 199118 
and the neuritic plaque staging by the CERAD19 (see Section 1.3.2) have been central 
for neuropathological AD diagnosis. The National Institute on Aging and the Ronald 
and Nancy Reagan Institute of the Alzheimer`s Association neuropathological AD 
criteria from 1997 combines the Braak and CERAD stagings, while also 
acknowledging that patients might have more than one type of pathology with impact 
on the clinical presentation. The recommendations include a grading of likelihoods 
that dementia in a patient is caused by AD, from high in patients with both neuritic 
plaques and neurofibrillary tangles in neocortex (Braak V/VI and frequent neuritic 
plaque score according to CERAD), to intermediate in patients with moderate 
neocortical neuritic plaques and neurofibrillary tangles in limbic regions (Braak III/IV 
and CERAD moderate) and low in patients with a limited distribution and severity of 





These criteria were again revised in 201214. On a conceptual level the new criteria 
emphasised the difference between neuropathological AD lesions, regardless of 
clinical setting, and “Alzheimer´s disease”, the clinical syndrome associated with 
significant AD neuropathology with a pre-clinical, a mild cognitive impairment and a 
dementia phase14. The revision also stressed the need to evaluate and recognize other 
kinds of pathology that might contribute to dementia. On a more practical level, the 
2012 criteria include also an A#-plaque score modified from Thal et al146 in addition to 
the neurofibrillary tangle score and neuritic plaque score based on Braak18 and 
CERAD19, and detailed recommendations for immunohistochemistry.  
  
As mentioned previously (in section 1.4.3), both the 199660, 200561 and 201762 DLB 
criteria have recommendations for the pathological diagnosis of DLB. The 2005 and 
2017 criteria also address the differential diagnosis versus Alzheimer´s disease, 
grading the likelihoods that the pathology found in a patient would be associated with 
the DLB clinical syndrome with varying degrees of AD pathology from low – 
intermediate and high. Whilst there are no generally accepted standard 
neuropathological consensus criteria for PD, traditionally an autopsy diagnosis has 
required degeneration of the substantia nigra pars compacta and Lewy body 
pathology81.   
 
In addition to ratings of amyloid, tau and !-synuclein aggregates, the presence of other 
pathology that might explain cognitive impairment such as TDP-43 proteinopathy 
often associated with FTD147 and vascular lesions148-150 should be carefully recorded 
before a neuropathological diagnosis is made. 
 
1.6" Literature"search"
For this thesis, the comprehensive literature searches ended on July 1st 2018. Some 











The general aim of this study was to increase our understanding of pathological 
mechanisms underlying important clinical features in neurodegenerative cognitive 




1)" To explore whether there is a link between CSF biomarkers and 
neuropsychiatric symptoms in early AD. 
2)" To examine whether early cognitive impairment in PD was associated with !-
synuclein, abeta42, t-tau or p-tau181 in CSF. 














All patients referred to specialist clinics in Old Age Psychiatry and Geriatric Medicine 
in Rogaland and Hordaland counties in Western Norway between 2005 and 2007 for 
dementia workups were screened, and those diagnosed with mild dementia were asked 
to participate. All Neurology clinics in the region were also invited to refer patients to 
the study. From 2007 - 2013 we selectively recruited DLB and PDD patients. 
Inclusion criteria were mild dementia, defined as a Mini Mental State Examination 
(MMSE)151 ≥  20 and/or Clinical Dementia Rating Scale152 of  ≤ 1. Exclusion criteria 
were delirium, previous bipolar or psychotic disorder, terminal illness or recent 
diagnosis of a somatic disorder that could affect cognition, function or study 
participation.   
 
The AD patients among the first 50 patients who underwent lumbar puncture were 
included in paper 1, n=32. 256 patients were originally included in the Demvest study, 




baseline evaluation. The neuropathology paper was based on the 56 patients who had 
come to autopsy by November 14. 2016, the autopsy cohort was compared to the 
patients who had died and not come to autopsy (n=149). At that time, 37 patients were 
still alive. One patient from the autopsy group was later excluded from the study as his 
cognitive impairment had not progressed after diagnosis.  
3.1.2(Parkinson’s(Disease(Progression(Markers(Initiative((PPMI)(
PPMI is a clinical cohort study of newly diagnosed PD patients > 30 years old from 24 
clinical sites in Europe, Israel and the United States. The study protocol and Case 
Report Form are published at ppmi-info.org, and data are publicly available through 
application to the Data and Publications Committee of the PPMI. Inclusion criteria 
were either asymmetric resting tremor or asymmetric bradykinesia, or two of the 
following; resting tremor, bradykinesia and rigidity, a PD diagnosis of two years or 
less at inclusion, a Hoehn and Yahr stage153 of I or II at baseline and positive DAT 
imaging154. Use of PD medication was an exclusion criterion, and for inclusion the 
patients should not be expected to require medication within the first 6 months154. The 
PPMI also included a healthy control group. Inclusion criteria for controls included no 
first-degree family member with PD, no significant neurological disorder and a 
Montreal Cognitive Assessment (MoCA) > 26155. Dementia was an exclusion criterion 
for the PD group. For both groups any conditions or drug that could interfere with 
dopamine transporter imaging such as neuroleptics and metoclopramide, or the safety 
of lumbar puncture, such as the use of anticoagulants were reasons for exclusion.  
 
In total there were 423 patients and 196 cognitively normal subjects in the PPMI 
database at the time of download in June 2014. For 6 patients and 7 controls, no CSF 
results were available from either the baseline or the first study visit three months 
later, and these were thus excluded. Three PD patients were excluded due to 







The baseline evaluation was done by a study clinician (Geriatrician, Old Age 
Psychiatrist or Neurologist) with help from a research nurse, and consisted in addition 
to a structured interview of patients and caregivers of a neuropsychological test 
battery, neuropsychiatric evaluation, standardized assessments of DLB symptoms, a 
general physical and a neurological examination, ECG, routine blood tests and 
assessment of dementia severity with the Clinical Dementia Rating Scale152. 
Caregivers completed the Informant Questionnaire on Cognitive Decline in the Elderly 
(IQCODE)156. Activities of daily living were assessed with the Rapid Disability Rating 
Scale-2157.  
 
The MMSE151 was used as a screening test of cognitive function. Verbal memory was 
tested using the California Verbal Learning Test158, language was tested using the 
Boston Naming Test159, visuospatial function by the Cube and Silhouette subtest of the 
Visual Object and Space Perception Battery160 and the clock-drawing test, executive 
function by categorical verbal fluency (asking the patient to name as many animals as 
possible in one minute), the Trail Making Test A and B161 and the Stroop Colour-
Word test162. The neuropsychiatric evaluation consisted of the Montgomery and 
Aasberg Depression Rating Scale163, where 10 items are scored from 0 (not present) to 
6 ( maximum severity),  the Apathy Scale164 where 14 items are scored from 0 (not 
present) to 3 (maximum severity), and the Neuropsychiatric Inventory (NPI)165. The 
NPI is a standardized interview of an informant, usually a spouse or off-spring with 
detailed and long-term information about the patients, about neuropsychiatric 
symptoms. The informant was asked about the presence of neuropsychiatric symptoms 
during the last four weeks. If the answer on a screening question was positive, the 
carer was asked to rate frequency from 1 - 4 (<1 a week, approximately once a week, 
more than once a week or every day) and intensity of these symptoms, based on how 
much these symptoms negatively affect the patient from 1- 3 (mildly, moderately or 




12 is maximum severity for each of the items, there are 12 items in total. Psychosis 
was defined in this study as the combination of the three items delusions, 
hallucinations, and agitation. 
 
Parkinsonism was rated by the United Parkinson’s Disease Rating Scale (UPDRS) 
motor subscale166 – a diagnosis of parkinsonism required two of the following 
bradykinesia, tremor, rigidity, and gait disturbance/postural instability. Fluctuations 
were assessed by the Clinician Assessment of Cognitive Fluctuation108 and the Mayo 
Fluctuation Questionnaire107, applying recommended cut - off scores. RBD was 
evaluated using the Mayo Sleep Questionnaire117, in which the bed partner answers 
specific questions about dream enactment behaviour; duration of symptoms, injuries to 
patient or bed partner, dream content and if movements match dream content. The 
structured interview included a question about any adverse reactions to antipsychotics.    
 
A structural MRI was performed in cases without contraindications; in those instances, 
a CT scan was conducted instead. According to the study protocol, all participants 
where the clinician suspected that DLB could be a differential diagnosis should have 
been referred to DAT imaging, but due to availability this was not possible in all cases.  
 
After the baseline evaluation, participants were followed up with an annual 
examination until death. These evaluations were similar, but less extensive, to that 
preformed at baseline. Biannual meetings were held between study clinicians to ensure 
inter- and intra-rater reliability and harmonize procedures for the first 10 years of the 
study.  
3.2.2(PPMI(
Data from the screening visit and the baseline visit (completed within 45 days after the 
Screening visit) in PPMI were used in this study, in addition to CSF results from either 
baseline or the visit 3 months after baseline.  For both patients and controls, these first 
two visits included a structured interview, neuropsychological and neuropsychiatric 




PD patients also completed The Movement Disorder Society (MDS) Unified 
Parkinson´s Disease Rating Scale parts (UPDRS) I-III167, disease staging with Hoehn 
and Yahr which was included in the MDS-UPDRS, and the Modified Schwab & 
England Scale rating ability to perform activities of daily living168. RBD, daytime 
sleepiness and other non-motor features of PD were also assessed. 
 
Cognitive functions were assessed by the MoCA155 and tests of different cognitive 
functions. Memory was tested using the Hopkins Verbal Learning Test Revised 
(HVLT)169. Visuospatial functions were assessed using the Benton Judgment of Line 
Orientation (the 15 item-version)170, executive function by three semantic fluency tests 
(number of fruits, vegetables, and animals said in 60 seconds), attention by the Letter-
Number Sequencing Test171 and the Symbol digit modalities test172. For cognitive tests 
with continuous scores, the PD results were converted to z-scores using the means and 
standard deviations from the control group. Cognitive domains were created by 
averaging z-scores from different tests of the same domains. Subtests from MoCA155 
were combined with the other cognitive tests when creating domains, to include as 
much information as possible. Memory was constructed with the average of the z-
scores for total immediate recall (encoding) and delayed recall (retrieval) on the 
HVLT169. Attention and executive function were combined in one domain (z-scores of 
Phonemic fluency (from MoCA155), Semantic Fluency, Symbol Digit Modalities 
Test172, and Letter-Number Sequencing171). The visuospatial domain was constructed 
using the z-score of Benton Judgement of Line Orientation173. In addition to the three 
domains, we constructed a global composite cognition factor; a single regression-
based factor score based on principal component analysis to reflect the common 
variance on all available cognitive tests in the whole sample of controls and patients. 
This composite cognition factor represented 34% of the variance in the whole test 
battery. With regards to imaging, structural MRI brain scan was available in addition 






Dementia was diagnosed according to the DSM IV174 criteria, which are similar (but 
not identical) to the ICD-104 criteria previously listed. The different dementia diseases 
were diagnosed according to the relevant research criteria available at study start in 
2005. Alzheimer’s disease was diagnosed according to the National Institute of 
Neurological and Communicative Disorders and Stroke-Alzheimer’s Disease and 
Related Disorders Association criteria175, DLB according to the 2005 DLB 
Consortium criteria61, vascular dementia the National Institute of Neurological 
Diseases and Stroke-Association Internationale pour la Recherche et l’Enseignement 
en Neurosciences criteria176 and dementia in Parkinson’s disease according to the 
recommendations from the Movement Disorders task force63. Alcohol dementia was 
diagnosed using the criteria from the DSM IV174, and frontotemporal dementia 
according to the Lund-Manchester criteria177. The first clinical diagnosis was made 
after the baseline visit, two psychiatrists with long experience in dementia diagnosis 
independently applied the diagnostic criteria based on all the information from the 
baseline visit including the case note from the clinician. In the event of disagreement, 
cases were discussed until consensus was reached. The clinical diagnosis were 
reviewed after both two and five years. The latter consensus process also involved an 
experienced geriatrician. The revisions focused on participants with previous 
“possible” AD/DLB/VaD diagnoses, or an unexpected clinical course, for instance, 
slow cognitive decline. All available information, including clinical records and 
neuroimaging, but excluding neuropathology were used in these revisions.   
3.3.2(PPMI(
A clinical diagnosis of PD within the last two years was required. The case report form 
has a specified list of diagnostic features increasing and decreasing the likelihood of 
PD and the clinician was required to note the presence or absence of each feature. 
Based in this, the clinician concluded as to whether the patient was likely to  have PD. 





PPMI was designed prior to the publication of the MDS task force criteria for MCI in 
PD178, and the neuropsychological test battery does not include two independent tests 
of each of the five cognitive domains as required for Level II “Comprehensive 
Assessment” in these criteria. Therefore, an approximation to these criteria was used, 
where subtests of MoCA155 were included as described previously179 to create the 
required five domains; executive function, attention and working memory, memory, 
visuospatial function, and language178.  
 
The memory domain was assessed by the total and immediate-delayed recall from 
HVLT169, the executive function domain using the semantic fluency tests in addition to 
phonemic fluency and the Trail Making item from MoCA, language by abstraction, 
sentence repetition and naming from MoCA, visuospatial functions using the clock 
and cube from MoCA in addition to the Benton Judgment of Line Orientation173, and 
finally attention was based on backward digit span, vigilance and serial 7s from 
MoCA in addition to the Symbol Digit Modalities Test172 and the Letter-Number 
Sequencing171. Impairment was defined as a result more than two standard deviations 
below the results in the control group, or inability to complete the MoCA item. 
Patients were defined as having MCI if they showed impairment on two or more tests, 
single domain MCI if both tests were within the same domain or multiple domain if 
there were impairment on tests across domains178.  The PD patients with impairment 
on $1 test were classified as PD with normal cognition.  
3.4" Biomarker"assessment"P"CSF"
3.4.1(Demvest(
Lumbar puncture was performed between 07 00 – 10 00, with the patients having 
fasted from midnight. The samples were kept on ice and transported to the laboratory 
where the first 3 mL were used for routine analysis of glucose, protein and cell count. 
Study samples were collected directly into polypropylene tubes, centrifuged at 2000 g 




were frozen at -80 and stored until shipment on dry ice to the central storage. Samples 
went through one freeze-thaw cycle for aliquoting to 0.5 mL tubes prior to analysis. 
Only polypropylene tubes and pipette tips were used.  
 
Total tau and tau phosphorylated at threonine 181 were analyzed using the 
commercially available Innotest enzyme linked immunosorbent assays (ELISAs) by 
Innogenetics (originally from Ghent, Belgium – merged with Fujirebio, Japan in 
2010). The abeta42 ELISA came from Biosource Europe S.A. Analysis were done 
according to the manufacturer`s protocols at a research laboratory at Stavanger 
University Hospital.  
 
These assays are sandwich ELISAs, the principles of which are explained briefly here; 
a capture antibody is bound to the solid phase – the bottom of the wells of a plastic 
plate. The sample is added and the peptide/protein binds to the capture antibody, after 
this stage the plate is washed to remove any peptide/protein not bound to the capture 
antibody. A secondary antibody against the peptide/protein is added, this antibody is 
labeled with the substrate for an enzyme. The plate is washed again to remove any 
secondary antibody not bound to a peptide/protein. An enzyme is added, and the 
interaction with the substrate produces a color change that is detected by a reader that 
measures absorbance at a specified wavelength of light, ”color intensity”. Standards 
with known concentrations of the protein /peptide in question are used to create a 
curve with absorbance vs concentration, and from this curve the concentration in the 
sample is calculated based on the absorbance.  
 
For t-tau, p-tau181 and abeta42 the standard range was 75 – 1200 pg/mL, 15.6 – 500 
pg/mL, and 15.6 – 1000 pg/mL, limits of detection were 59.3 pg/mL, 15.9 pg/mL and 
< 10 pg/mL respectively. Intraassay coefficient of variation (%CV) were 1.2 – 5.9 in 
the t-tau assay, < 5.0 in the p-tau181 assay and %3 in the abeta42 assay, inter-assay CV 





CSF was collected in siliconized polypropylene tubes and the first 1-2 mL sent to the 
local laboratory for routine analysis of cell count, total protein levels and glucose 
level. The next 15 – 20 ml was centrifuged at 2000 g for 10 minutes at room 
temperature, and then transferred into precooled 1.5 ml tubes that were immediately 
frozen using dry ice. The frozen aliquots were shipped overnight to the PPMI 
Biorepository Core laboratories on dry ice. Samples were thawed there and aliquoted 
into 0.5 ml siliconized polypropylene tubes and stored at -80° C until analysis.  
 
Abeta42, t-tau and p-tau181 were analysed as described previously180, 181 using the 
multiplex Luminex xMAP platform (Luminex Corp) with INNOBIA AlzBio3 
(Fujirebio-Innogenetics, Ghent, Belgium) kit reagents at the University of 
Pennsylvania. The Luminex assays are based on the capture antibody being bound to 
beads instead of the bottom of the well as a traditional sandwich ELISA; one type of 
bead is covered with a specific type of target antibody, and several kinds of beads can 
be added to the same sample, thus having the major advantage of allowing for the 
concomitant analysis of several peptides/proteins. In the last step, one laser frequency 
recognizes the type of bead and a second laser the amount of bound protein to that 
specific kind of bead (for more information, www.luminexcorp.com). Briefly, 75 µl of 
samples, standards, aqueous controls and two pooled CSF samples used for quality 
control were analysed in duplicate. After 38 runs, mean variability of concentrations 
(%CV) were 9.0, 6.7 and 8.2 for abeta42, t-tau, and p-tau181 respectively in the 
pooled CSF samples. The results for t-tau in 6 baseline samples (four PD and two 
healthy controls) did not meet quality requirements and were excluded from further 
analysis. Α-synuclein and CSF haemoglobin levels were analysed using commercially 
available sandwich ELISA kits from Covance (Dedham, MA) at Covance. A total of 
81 runs were conducted, and the CV for two quality control CSF samples was 17% for 
α-synuclein. The haemoglobin assay had standards in a range of 7.5 – 125 ng/ml, and 
samples were analysed at 3 dilutions to secure that at least one dilution fell within the 





As the levels of α-synuclein in blood cells are much higher than in CSF, blood 
contamination of CSF, which is not uncommon, may influence results182.  306 controls 
and PD patients had CSF haemoglobin values below the detection limit, and for 131 
no CSF haemoglobin values were available at the date of data download. For some 
individuals, more than one CSF haemoglobin value was available, in these cases, the 
one closest to the date of the α-synuclein analysis was selected.   
 
As expected, CSF α-synuclein and CSF haemoglobin concentrations were correlated 
(all PPMI samples, including subjects without evidence of dopaminergic deficits, 
Spearman Correlation coefficient 0.092, p=0.036). A more detailed analysis of the data 
suggested correlation was driven by five outliers with extreme α-synuclein values (> 3 
standard deviations (SD) above the mean). After exclusion of these outliers, there was 
no longer a significant correlation between α-synuclein and haemoglobin. To further 
explore the relationship between α-synuclein and haemoglobin, the dataset was 
subdivided into 4 groups; haemoglobin below the detection limit, haemoglobin > 
detection limit < 200 ng/ml, haemoglobin > 200 ng/ml and haemoglobin missing. A 
Kruskal-Wallis test for independence was performed, and CSF α-synuclein values 
were found to be similar in these groups. Thus the five PD patients with α-synuclein > 
3 SD above the mean were excluded from further analysis.  
 
DNA was extracted from whole blood, and APOE genotypes determined using allele-
specific oligonucleotide probes (TaqMan method). TaqMan assays were used 
according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA)180.  
3.5" Neuropathological"diagnostic"procedures"
3.5.1(Demvest(
The details of the sampling of brain regions, immunohistochemistry and antibodies are 
described in the original paper. Briefly, the BrainNet Europe and Brains for Dementia 




tissue processing, and staining and block taking for both histological, 
immunohistological and neuropathological assessments14, 142-145.  
 
Specific stains were used for immunohistochemical characterization of #-amyloid 
(diffuse and classical plaques and amyloid angiopathy), hyperphosphorylated tau 
(dystrophic neurites, pretangles, tangles, and neuropil threads) and !-synuclein 
pathology (Lewy neurites and Lewy bodies) according to the protocols mentioned 
above. Any TDP-43 pathology was assessed according to the appropriate guidelines147, 
and vascular lesions such as small vessel disease and infarctions were recorded148. 
 
Cases were evaluated by an experienced neuropathologist (TH) who was blinded for 
all clinical information. Neuropathological diagnoses were made according to 
accepted consensus criteria for AD14, 18, 19, 25, DLB61, 82, 144 and VaD149, 150. Patients 
were classified as having LBD if the likelihood of the pathology being associated with 
the DLB syndrome was intermediate or high according to the 2005 McKeith criteria61. 
Cases diagnosed neuropathologically as LBD were given a pathological diagnosis of 
DLB if the clinical diagnosis was DLB and PDD if the clinical diagnosis was PDD. 
One case was difficult to classify according to the protocols mentioned previously, 
with Lewy body pathology displaying an atypical pattern of distribution. The Lewy 
body pathology was labeled “mostly limbic”, and the case diagnosed as AD due to 
severe AD with Braak neurofibrillary tangle stage VI. 
3.6" Statistical"analyses"
3.6.1(Simple(comparisons(and(correlation(analyses(
Data were analysed using several editions of SPSS Statistic. p < 0.05 was considered 
statistically significant. When demographic variables and CSF marker results were 
compared between groups the Student´s t-test, the Mann-Whitney test, Fischer`s exact 
test or Chi-square test were used as applicable. The distribution of the original data 
was checked using the Kolmogorov-Smirnov statistics and simple scatter plots.  When 




and PPMI cohorts non-parametric analyses were used including Spearman 
correlations. Sensitivity and specificity were calculated using appropriate formulas and 
2 x 2 tables, see table 4183. Cohen´s kappa (&) measure of agreement was calculated as 
follows, using the letters from table 4 in the equations. Observed measure of 
agreement = Io = (a+d) /n. Expected measure of agreement = Ie = 





As mentioned in 3.2.2, cognitive domains (attention/executive, memory, visuospatial 
functions) were created by combining tests of the same domain, in addition to a 
composite cognition factor representing common variance on cognitive tests. To 
explore whether the CSF markers influenced cognition, four different multiple linear 
regression models were constructed, with the cognitive domains and the composite 
cognition factor as dependent variables. As a first step, only the CSF markers were 
added. As a next step, the models were adjusted for potential confounders including 
age, gender, education and APOE status (presence of an APOE "4 or "2 allele), in 
addition to total MDS-UPDRS III score167. APOE genotype did not prove significant 
in any of the models and was thus not included in the final analysis (see table 6 for the 
final models). To compare CSF marker concentrations between PD-MCI and PD with 




adjusted for other factors with possible impact on cognition, such as gender, age, 
education, the severity of PD rated with the MDS-UPDRS III167 score and other 
markers. The predictors were added in different fashions, demographics and MDS-
UPDRS III167 were added as forced entry, while the other CSF markers were added 
stepwise. The regression analyses were checked for multicollinearity using as 
recommended by Belsley and Kuh184, and also for leverage, heteroscedasticity and 
normality of residuals, and did not violate assumptions. However, there was a trend 
towards non-normality of the residuals in the analysis of the visuospatial variable.  
 
3.6.3(Missing(data((
All the 32 AD patients in paper I had results on all three CSF markers. The Spearman 
correlations were explored in all patients with available neuropsychiatric assessment 
results, without any adjustments for missing data. In the PPMI cohort, only patients 
without missing values were included in the analysis (n=403), (5 were excluded 
because of extreme !-synuclein values, two due to missing p-tau181, and 4 due to 
missing t-tau results). 38 PD patients had no APOE results, but as mentioned APOE 
genotype was not included in the final models. Thus the patients included in the 
models had complete data sets for both the demographic variables, neuropsychological 
tests, and CSF marker results.  
 
Four of the autopsied (n=56) and six of the non-autopsied patients (n=149) in the 
Demvest cohort were missing information about disease duration prior to diagnosis. 
Demographical information, baseline MMSE151 scores and disease duration from 
diagnosis to death the data were available for all.  
 
3.7" Ethical"approval"
The project followed the recommendations from the Helsinki declaration. The 




research ethics in western Norway (REK 2010/633). The patients all had mild 
dementia at inclusion and were thus considered able to consent on their own behalf. 
The study procedure was explained to all patients in the presence of a carer, and the 
study participant provided written consent. All patients were asked to consent for both 
lumbar puncture and autopsy, however it was also possible to participate in only the 
clinical part of the study. The PPMI study was approved by the medical ethical 
committees at the respective centres. Written informed consent was obtained from all 











Our sample were majority female (71% women), mean age was 73.9 years (SD 9.0). 
Mean duration of disease since the first symptoms were noted by carer or patient were 
2.1 years (SD 1.1), and the patients had mild dementia with a mean MMSE score of 
24.2 (SD 2.3). We found significant correlations between the t-tau and p-tau181 
concentrations and apathy, assessed with Starkstein apathy scale164, see table 5 and 





CSF abeta42 was not associated with any of the neuropsychiatric symptoms. No 
significant correlations were found between depression and psychosis and the markers, 
neither when the NPI165 delusions, agitation, and hallucination items were analysed 










CSF !-synuclein, t-tau and p-tau181 concentrations in CSF were significantly lower in 
the 414 PD patients compared to the 189 healthy controls (p<0.001, p=0.001 and 
p=0.001), in contrast abeta42 concentrations were similar. T-tau and !-synuclein 
correlated significantly with age in the whole cohort of patients and controls 
(Spearman´s correlation coefficient 0.209, p<0.001 and 0.123, p=0.002 respectively), 
and in the PD patients (Spearman´s correlation coefficient 0.276, p<0.001 and 0.140, 
p=0.004), while in the control group only t-tau correlated with age (Spearman´s 
correlation coefficient 0.337, p<0.001).  
 
140 PD patients (34%) had MCI and the remainder normal cognition. Of those with 
MCI, 7% had single domain and 93% had multiple domain MCI. The PD-MCI 
patients were older (p=0.005), less educated (p<0.001) and had more severe motor 
impairment reflected in higher UPDRS-III167 scores (p=0.013) than the other PD 




controls (p=0.033) after adjusting for age, education, the severity of PD and the effect 
of the other CSF biomarkers, but no significant difference was found between PD 
patients without cognitive impairment and controls. The CSF concentrations of !-
synuclein, t-tau and p-tau181 were significantly lower in both the PD-MCI and the PD 
patients with normal cognition compared to healthy controls, but no differences were 
found in marker concentrations between PD-MCI patients and PD patients with 
normal cognition.  
Relationship(between(CSF(markers(and(cognition(
The next stage was to analyse the associations between the composite cognition factor 
and cognitive domains and the CSF markers in multiple regression analysis (Table 6). 
In the models adjusted for all covariates (age, education, gender, total UPDRS-III167 
score), low !-synuclein was significantly associated with reduced cognitive function 
both assessed with the composite cognition factor (standardized beta =0.132, p= 
0.019) and the executive function / attention domain (standardized beta = 0.137, 
p=0.020). Reduced !-synuclein was also associated at trend level with both the 
memory (standardized beta 0.109, p= 0.068) and visuospatial domains (standardized 
beta=0.118, p=0.058).  
 
Increased t-tau was significantly associated with decreased function in the 
executive/attention domain (standardized beta= -0.216, p=0.001) and visuospatial 
function (standardized beta=-0.181, p=0.008), but the associations were no longer 
significant when the other covariates were added to the model. No significant 










Gender, education and baseline MMSE were similar in the autopsy cohort (n=56) and 
the non-autopsy cohort (n=149) (see Table 1 in the original publication). The autopsy 
group was somewhat younger at baseline (mean age 74.0, SD 8.2 versus 77.2, SD 6.8, 
p=0.025) with longer survival after the baseline evaluation (mean 76.4 months, SD 
29.0 versus 54.3 months, SD 30.6, p<0.001) than the non-autopsy cohort.  
 
As it is not possible to separate DLB and PDD neuropathologically, these are referred 
to as LBD when reporting the neuropathological diagnoses. Of the 56 patients who 




vascular dementia and one case each of progressive supranuclear palsy, TDP-43 
positive frontotemporal dementia and no significant pathology. The patient without 
significant pathology had already been excluded from the main study because the 
cognitive impairment did not progress. One patient with Braak !-synuclein stage 382 
and no other pathology (Braak tau stage I and only mild small vessel disease) was 
classified as LBD, with a clinical diagnosis of PDD. This patient was clinically a clear 
cut PD patient with response to levodopa, but increasing cognitive impairment and 
visual hallucinations. The patient died at 61, just one year after inclusion.  
 
The neuropathologically confirmed LBD cases had a significantly shorter duration 
from diagnosis to death compared with the neuropathological AD patients, mean 
survival of 60.9 months (SD 27.8) and 87.0 months (SD 23.9, p=0.002) respectively. 
Age, education, baseline MMSE results, and disease duration prior to diagnosis were 
similar in the neuropathological AD and LBD groups.  
 
Concomitant pathologies were common; 10 AD patients had some Lewy body 
pathology, including three restricted to the amygdala only. Varying degrees of AD 
pathology was present in nearly all LBD patients. TDP-43 pathology was common, 
found in 9 AD patients and 6 LBD patients. Vascular pathology, such as amyloid 
angiopathy and small vessel disease was common in both AD and LBD, some patients 
also had cerebral infarctions.  
 
Among the 14 patients with clinical probable DLB, 11 had pathological LBD and 
three had AD. One patient had clinical possible DLB but pathological AD. Of the 20 
patients with neuropathological LBD, 11 had a clinical DLB diagnosis, five a clinical 
PDD diagnosis, two had probable and two had possible AD. A clinical LBD diagnosis 
had sensitivity, specificity, positive and negative predictive values of 80%, 92%, 84% 
and 89% for DLB and PDD combined. If the PDD patients were excluded, clinical 
probable DLB had sensitivity, specificity, positive and negative predictive values of 




between clinical and neuropathological DLB diagnoses were 88%, Cohens & measure 





Details about the neuropathology and the presence of core DLB features at the annual 
assessments in the “false negative” and “false positive” DLB patients can be found in 
Table 4 in paper III. None of the four false negative patients, that is patients with 
pathological but not clinical LBD had any of the core features at baseline. However, 
three of the four had no bed partner and polysomnography was not performed, thus the 
presence of RBD could not be properly assessed. UPDRS-III166 scores were slightly 
elevated in two of the false negatives, 11 and 9 at baseline respectively, with 
significant progression at follow up. One of the four also developed cognitive 
fluctuations and visual hallucinations. MRI showed hippocampal atrophy in all of 
these cases. In the two patients without parkinsonism, one developed fluctuations and 
visual hallucinations from the third follow up which persisted. The other patient was 
entirely without core features until the 5-year follow-up, after which she developed 
both cognitive fluctuations and visual hallucinations. The pathological assessment 
showed severe AD pathology in all these false negative cases, with Braak tau stage 





Three patients were false positives; meaning they were diagnosed clinically as LBD, 
but this was not verified at pathology. All three had both visual hallucinations and 
fluctuations at baseline, which persisted for several years. MRI showed relatively 
preserved hippocampal regions. Importantly, two of the patients had impaired vision, 
one of them on both eyes. Their parkinsonism increased gradually and was moderate 
to severe 3 years after baseline, but two of them had received treatment with 
antipsychotics. However, both these patients still fulfilled the DLB dignostic criteria 
also without the parkinsonism, due to the presence of fluctuations and visual 
hallucinations. Neuropathology showed that all three had severe AD with Braak tau 
stage VI. Whilst the two patients with eye disease had no Lewy body pathology, 
neurofibrillary tangle pathology was present in the substantia nigra, and in one of them 
TDP-43 pathology was present in the amygdala and hippocampus. These two patients 
were the ones with eye disease. The third patient had limbic !-synuclein pathology in 
addition to amyloid angiopathy and small vessel disease. This case did not readily fit 
into the McKeith DLB criteria62, with Lewy body pathology skipping the substantia 




This section will start with a discussion of our methods (5.1). I will review strengths 
and limitations in our patient sampling, clinical assessments, CSF analysis, 
neuropathological analysis and statistical methods and how this might have influenced 
results. The next segment (5.2) is a discussion of our results. I will compare our 
findings to those of others, discuss similarities and discrepancies, explore implications 




The Demvest study is not population-based, but rather patients referred to specialist 
clinics in Geriatric Medicine and Old Age Psychiatry for dementia work-ups. An asset 
of the study is that all relevant specialist clinics in the Hordaland and Rogaland 
counties in Norway participated. However, in Norway, many persons with dementia 
are diagnosed by primary care physicians, and the patients referred to specialist clinics 
may not be representative for the total dementia population. An overrepresentation of 
patients with neuropsychiatric symptoms, other non-cognitive symptoms or an atypical 
course is likely. This might have influenced results in paper I.   
 
The prevalence of DLB is higher in secondary than primary care settings64. For the 
first two years of the study period, all referrals were screened, resulting in 16% DLB 
of newly diagnosed dementia patients. This is higher than recent findings from 
specialist clinics in the UK were DLB constituted 5% of incident dementia cases185, 
although in the population based Islington study DLB constituted 11% of dementia  
cases > 65 years186. Later DLB and PDD patients were recruited selectively in 
Demvest and are thus overrepresented. The Demvest cohort included 32% DLB and 
7% PDD based on clinical diagnosis after 5 years. Prevalence does not affect estimates 




the positive predictive value and decreased the negative predictive value in paper III 
compared to populations with lower LBD prevalence. 
 
The PPMI patients were mainly from University clinics and thus not representative for 
all PD patients. They were younger than patients in other cohorts of newly diagnosed 
PD patients, with a mean age of 61.3 years compared to mean 65.9187 and 67.667 years 
in two population-based cohort studies of newly diagnosed PD. Our PD and control 
groups were highly educated with a mean education of 15.6 and 16.0 years 
respectively. In comparison, 34% in the United States population born between 1948 – 
1952 (corresponding to the age bracket of the majority of the PPMI patients) had 
completed a bachelor’s degree or higher (corresponding to ' 16 years of education)188. 
Age and education are important factors in explaining why the PPMI patients had 
better cognition at baseline than other cohorts, mean MoCA score in PPMI was 27.1 
compared to 25.3187 and approximately 23-24 (converted from MMSE 27.8)189, 190 in 
others. This might have decreased the strength of our associations, as higher education 
likely causes individuals to perform better cognitively even when harbouring 
pathology1. The requirement of a positive DAT imaging for inclusion as a PD patient 
separates our cohort from many other PD cohorts. This strengthens our ability to find 
significant associations if present, as it increases the probability that included patients 
have PD. 
Clinical(patient(assessments(
Strengths of both the Demvest and PPMI cohort include the extensive subject 
characterization and the long duration of follow-up in the Demvest. Few studies have 
followed patients from dementia diagnosis to death with yearly follow up as the 
Demvest study did. This gives an opportunity to follow the development of symptoms, 
unlike studies that are either based on diagnoses from a single baseline interview or 
have a long interval between the last follow-up and autopsy.  
 
Limitations to the Demvest study include that only 50 of 242 were evaluated with 
DAT imaging, only 56 has yet come to autopsy. Presence of RBD was assessed using 




our ability to detect RBD depended on whether the carer had observed the patient 
sleep, and was likely lower in patients without a bed-partner. Polysomnography and 
DAT imaging in all patients would have increased the accuracy of clinical diagnosis.  
 
When assessing neuropsychiatric symptoms in dementia some scales are rated by 
informants/carers and others by the patients themselves; these may measure different 
concepts. We applied a specific scale for apathy, whereas several other studies relied 
solely on the NPI165 apathy item. A broader neuropsychological test battery in PPMI 
would have strengthened our cognitive domains. However, on the other hand, too 
many instruments and tests might increase the risk of missing data and drop-outs, and 
thus reduce the quality of the dataset. The multicenter design of both PPMI and 
Demvest with the involvement of a large number of clinicians increases the risk of 
both random and systematic errors of testing, application of standardized scales and 
the diagnostic processes. Random errors would decrease the strengths of our 
associations, thus making us prone to type II errors, systematic errors could make our 
results inaccurate. On the other hand, for paper III the multicenter design involving all 
relevant out-patient clinics in the catchment area makes results more applicable to 
general clinical practice than if the study were conducted in a tertiary centre 
specializing in DLB.  
Subsamples(vs(the(whole(cohort(in(Demvest(
Gender, baseline MMSE scores and education were similar in the autopsy and non-
autopsy groups, but patients in the autopsy group were somewhat younger at inclusion 
and had longer survival. There are several possible reasons for this. Firstly, it took 
some time from study start until all logistics with the three participating pathological 
departments and undertakers had been properly established. Secondly, some patients 
required more time to reflect and discuss with family and did not consent to autopsy at 
the first visit. Thirdly, most of the patients with long survival lived in nursing homes 
where regular visits from study nurses and physicians and information about autopsy 
procedure in the patient files may have increased the likelihood of autopsy being 






The PPMI design did not include a neuropsychological test battery sufficient for a 
level II MCI diagnosis according to the MDS MCI in PD criteria178, thus we had to 
make adjustments which might have decreased the accuracy of the MCI classification. 
We report a MCI prevalence of 34%, in the newly diagnosed and untreated PD 
patients. Other studies using the level II MDS criteria have found a MCI prevalence of 
20% - 65% in PD, but not all these patients were newly diagnosed191. Reports of MCI 
prevalence in newly diagnosed PD are somewhat conflicting. Some are similar to our 
findings (35%192 and 33%193), while one population-based study a found higher 
prevalence (43%)187 and another population-based study a lower prevalence (19%) in 
an older and less educated cohort67. Weintraub and coworkers found that 22% of the 
PD patients in the PPMI cohort fulfilled MDS level I criteria for MCI in PD, but only 
9% were classified as MCI according to their approximation to the level II criteria194. 
The MDS level II MCI criteria define impairment as “performance between 1 to 2 
standard deviations (SDs) below age, education culturally applied norms…”178.  
Weintraub and coworkers MCI classification was based on published norms for the 
neuropsychological tests, however, only two of the five tests were adjusted for 
education194. This may have led them to falsely classify highly educated PD patients 
with impaired cognition as cognitively intact. This, in addition to the fact that they 
chose 1.5 standard deviations below the meanwhile we chose 2 standard deviations, 
may partly explain the discrepant results. 
 
The PPMI required controls to have a MoCA score above 26. A population-based 
Norwegian study of 63 – 65-year-olds (n=3413) found that mean MoCA score was 
26.2 (SD 2.5) in the group with the highest level of education ( > 12 years) and thus 
most comparable to the PPMI controls and patients195. Although test results improved 
significantly with education195, and the PPMI patients and controls on average have 
more education than 12 years, there is a substantial risk that the PPMI control group 
might have superior cognition to even similarly educated populations. For PD patients, 
the criteria for cognition was merely no dementia, and the PD group had significantly 





Our MCI classification was based on comparisons with the control group for tests with 
a continuous score and results below the maximum possible score on the MoCA 
subtests. Two factors may have caused us to overestimate the MCI prevalence. Firstly, 
our inclusion of several MoCA items, where impairment was defined as a result below 
the maximum. As the Norwegian normal population with similar education in the 
relevant age group miss on average 4 points on the MoCA, this was likely too strict195. 
Secondly, comparing the PD patients to the probably supra-normal control group 
could lead to overestimation of MCI. Potentially compensating for this is that with a 
mean MoCA score of 27.1194 the PD patients likely also had supra-normal cognition as 
well as the fact that we choose to define impairment as a result two SD below the 
mean in the control group, rather than the 1.5 SD which is frequently used. The PD-
MCI group had lower education, higher UPDRS-III scores and were older than PD 
without cognitive impairment and the control group. Thus the limitations listed above 
may have led to misclassification of older individuals or those with low education as 
PD-MCI. We found a somewhat surprisingly high prevalence of multiple domain MCI  
(93%), this is in line with others applying the MDS MCI criteria, between 65 – 93% 
multidomain MCI have been reported191.  
 
5.1.2(CSF(analysis(
CSF marker analysis in dementia has been hindered by pre-analytical and analytical 
variation. Abeta42 is especially challenging, as it is a lipophilic protein and binds to 
surfaces in a non-specific manner7. The Task Force on Biological Markers in 
Psychiatry of the World Federation of Societies of Biological Psychiatry has published 
an update where pre-analytical and analytical factors are extensively reviewed, in 
addition to the work being done to overcome these obstacles7.  
 
Much of this evidence has been gathered during the last decade, after the CSF 
collection in the Demvest project started in 2005. A standardized lumbar puncture and 




recommendations in later guidelines were followed: we did not distribute tubes to the 
different centres, so different polypropylene tubes were used prior to shipping to the 
central storage, the CSF was frozen in smaller aliquots than are now recommended, we 
failed to fill tubes to 75 % of the volume after aliquoting and we labelled tubes 
manually, not with bar codes7. ELISA procedures were manual, relying on manual 
pipetting to a 96 well plate. Fully-automated assays have shown more stable 
measurements7. This might have influenced especially abeta42 concentrations and 
made our analysis less reliable. Most likely these factors have caused random errors, 
thus decreasing the strengths of our associations, but systematic errors cannot be ruled 
out.  
 
For abeta42 analysis, we used an ELISA assay from Biosource, while t-tau and p-
tau181 were analyzed with Innotest ELISAs (see Methods section 3.4.1). The Demvest 
samples were reanalyzed at Sahlgrenska University Hospital, Mӧlndalen as part of a 
multicenter study with Innotest total tau, Innotest p-tau181 and Innotest β-amyloid(1-
42) ELISAs196. Correlations were good for total tau and p-tau181, with Spearman`s 
rho = 0.911 and 0.900 respectively (p<0.001 and p<0.001). However, the abeta42 
results were less satisfactory, with rho 0.427 (p=0.002). Thus our t-tau and p-tau181 
results are comparable to other studies, the abeta42 results less so.  
 
The PPMI was designed years later and carefully planned to minimize pre-analytical 
variation. All centres received kits with all the material required for lumbar puncture 
and CSF handling. The “Biospecimen Collection, Processing, and shipment Manual” 
(see ppmi-info.org) describes the CSF handling in detail. A training video for correct 
CSF processing and aliquoting was made. However, it was a limitation that not all 
patients and controls had available CSF haemoglobin concentrations at the time of 
data download. But as described in the methods section, we took precautions to 






Brain dissection, tissue preparation, staining, immunohistochemistry and staging of 
pathology for paper III were done according to international consensus protocols, see 
the methods section. Not being a neuropathologist, I will not discuss the methods used 
further. However, some steps of the neuropathological diagnostic process warrant a 
comment. Many patients had several pathologies present at autopsy. Both the 200561 
and 2017 DLB62 criteria acknowledge that many patients have concomitant Lewy 
body and AD pathology, and provide the likelihood of a clinical DLB syndrome for 
different combinations of Lewy body and AD pathology (see Introduction section 
1.4.3).  In Paper III we chose to classify patients with a neuropathological 
“intermediate” or “high” likelihood of the DLB syndrome as DLB62. If only those with 
“high” likelihood had been classified as DLB, this would have increased sensitivity to 
a 100% for a clinical diagnosis of DLB; as all of the eight “high” likelihood cases had 
a clinical diagnosis of PDD or DLB. But decreased specificity to 83%, as six cases 
with a clinical DLB diagnosis had neuropathological “intermediate” likelihood. Also, 
two PDD cases did not fulfill criteria for “high” likelihood of DLB. 
 
5.1.4(Statistical(analysis(
The sample for paper I contained only 32 patients, thus there is a clear risk for type II 
errors, there may have been real correlations that we were unable to detect due to low 
power. A limitation to the statistical analysis in Paper I was unadjusted correlations. T-
tau increases with age in healthy individuals197, 198 and memory clinic patients199, while 
p-tau181 levels are stable198, 199. Whilst the prevalence of apathy has been found to 
increase with age in non-demented elderly200, 201, this is not the case in  AD patients38. 
Thus age is unlikely to have an effect on our results. Apathy has on the other hand 
been found to be associated with the level of education and dementia severity, perhaps 
as explained by lower education contributing to more severe cognitive impairment38. 
Thus, ideally we should have adjusted for education and dementia severity, but 




due to dementia severity was reduced by our inclusion criteria; all patients had mild 
dementia.  
 
The large sample size is a major advantage for paper II. Limitations to the 
generalizability of results of paper II include that the standardized beta values were 





We explored the correlation between neuropsychiatric symptoms and CSF biomarkers 
in early AD, both out of interest in the neuropathological underpinnings of these 
symptoms, and because of reports of an association between neuropsychiatric 
symptoms and dementia progression38, 202 and conversion from MCI to dementia203. 
Our main finding was a correlation between apathy and t-tau and p-tau181 
concentrations in CSF. Few other studies have explored this. Contrary to our findings, 
t-tau and p-tau181 were not associated with severity of apathy at baseline, nor its 
development over time in a cohort of normal controls, MCI and AD patients54. This 
discrepancy may be explained by different patient groups and the use of a 
questionnaire version of the NPI to assess apathy in the other cohort204. We used the 
Starkstein Apathy Scale164, which maps more aspects of apathy and is self-reported 
while the NPI is based on reports from a carer. In the Demvest cohort there were no 
associations between apathy and t-tau and p-tau when apathy was measured with the 
NPI apathy item (Spearman´s rho 0.062, p=0.756 and Spearman´s rho -0.16, p=0.935 
respectively), thus supporting the theory that a specific, self-reported instrument 
measures something separate from a single NPI item.  
 
Apathy is a symptom of vital importance for dementia patients, it is a strong predictor 




and thus of the patient`s ability to live independently. Apathy is likely the most 
common neuropsychiatric symptom in dementia38, 40, 206, reported to have both high 
incidence over time and high persistence40. In the Demvest study, apathy was the most 
prevalent neuropsychiatric symptom, increasing in AD patients over time202. Thus 
apathy is both common and persistent in AD, this adds weight to the theory that apathy 
may be linked to core AD pathology. Our findings of an association between increased 
p-tau181 and t-tau in CSF and apathy may suggest a role for neurofibrillary tangle 
pathology in its pathogenesis. The increased t-tau also concentration also  suggests that 
neurodegeneration might be involved, as t-tau concentrations likely reflect the 
intensity of neuronal damage7.   
 
Prefrontal regions and the anterior cingulate are frequently associated with apathy in 
both structural and functional imaging studies of AD and MCI patients207. The anterior 
cingulate is associated with cerebral processes underlying goal-directed behaviour 
involving emotion, initiative and cognitive interest, and prefrontal regions are 
important for planning and strategic thinking207. This has led to theories that apathy in 
AD might be caused by dysfunction in these structures and/or circuits involving these 
regions207. Cholinergic and dopaminergic denervation have also been linked to 
apathy208, and the theory that dopaminergic dysfunction is involved has been 
supported by a few randomized controlled studies finding that methylphenidate 
reduces apathy in dementia208.  
 
As the neurofibrillary tangle pathology starts in the transentorhinal cortex, frontal 
regions and the cingulate are first affected at later stages18. However, our findings of 
an association between the CSF markers of neurofibrillary tangle pathology and 
apathy are in line with two neuropathological studies reporting a correlation between 
neurofibrillary tangle load in the anterior cingulate region and apathy scores209, 210, 
thus integrating our hypothesis with the finding from imaging studies of anterior 





Our finding of no associations between CSF markers and depression in the newly 
diagnosed AD patients has since been replicated in AD211 and MCI patients (mainly 
amnestic MCI)212. In line with our findings of no association between the CSF marker 
of beta-amyloid pathology and depression, no correlation was found between current 
depressive symptoms and cortical beta-amyloid depositions quantified with 18F-
florbetapir PET in MCI and AD patients49. Contrary to this, an autopsy study found 
higher levels of both amyloid plaques and neurofibrillary tangles in the hippocampus 
of AD patients with depression, compared to those without a history of depression213. 
Patients with depression also had a more rapid progression213. A higher density of 
beta-amyloid depositions assessed with 18F-florbetapir have been found in the frontal 
cortex of amnestic MCI patients with a lifetime history of depression compared to 
their counterparts without previous depression214, and in multiple brain regions in 
persons with a lifetime history of depression compared to those without previous 
depression215. Thus, whilst the evidence suggests an association between lifetime 
depression and beta-amyloid pathology, the same has not been shown for current 
depression in AD. Depression is an AD risk factor1, more research is needed to 
ascertain whether the mechanism underlying this is depression driving beta-amyloid 
accumulations, as well as other possible mechanisms such as hypercortisolemia216.  
Psychosis(
In contrast to our findings of no associations between psychosis and CSF markers, 
another study reported that CSF t-tau, but not p-tau181, was elevated in AD patients 
with psychosis at baseline or who developed psychosis over a 36-month period 
compared to those without psychosis217. Elevated t-tau alone, however, likely 
represents neuronal damage in general, and is not specific for AD7. The diverging 
results could be explained by larger sample size, they included 200 AD patients, and 
the longitudinal design, as psychosis is more common in moderate than mild 
dementia1. We included the agitation item of the NPI165 in our definition of psychosis. 
In a study where a comprehensive assessment for agitation was included, agitation 
correlated with CSF t-tau and p-tau181 in dementia218. In 728 patients with a 




amyloid plaque or neurofibrillary tangle pathology and psychosis (hallucinations 
and/or delusions) present at any time assessed using the NPI219. Thus our findings of 
no association between AD CSF markers and psychosis are mostly in line with other 
findings. However, comorbid Lewy body pathology, subcortical white matter lesions 
and vascular risk factors smoking, hypertension, diabetes and amyloid angiopathy are 
significantly associated with psychosis219, 220. 
A(broader(perspective(on(neuropsychiatric(symptoms((
Although neurobiological mechanisms likely play a role for neuropsychiatric 
symptoms, psychological, social, environmental and other mechanisms also 
contribute. With increasing dementia severity, the individual’s ability to understand 
his or her surroundings, and communicate thoughts and needs are gradually lost. 
Psychological theoretical frameworks focus on triggers and reinforcements of the 
unwanted behaviour, on behaviour as a way to communicate unmet needs, and on 
symptoms as a reaction to an environment with too many stressors221. Both medical, 




As mentioned in the introduction, amyloid plaques and neurofibrillary tangle 
pathology are associated with cognitive impairment and dementia in PD5, 222. Our 
finding of decreased CSF abeta42 in the PD-MCI group after adjustment for covariates 
is in line with previous findings of decreased abeta42 in PD with cognitive impairment 
and dementia223, 224. Previous studies have found that decreased CSF abeta42 
concentrations correlate with memory impairment in PD187, 189, 225, 226. Our study did 
not reproduce this, we found no association between decreased abeta42 and 
impairment of the memory domain. Discrepancies between our study and the previous 
publications might be due to differences in patient characteristics; the PPMI patients 
were younger and less cognitively impaired, and all were unmedicated187, 189, 225, 226. 
Two of the previous studies included PD patients with disease duration of several 




longitudinal studies73, 74, 224, 227, including in the PPMI-cohort228. The same has been 
shown in DLB131. Thus, our findings support results from previous publications; 
decreased CSF abeta42 is associated with cognitive impairment in PD.  
 
We found decreased t-tau and p-tau181 in PD patients compared to controls, but no 
association between t-tau or p-tau181 concentrations and cognition. Results regarding 
the relationship between t-tau and p-tau181 in CSF and cognition in PD are 
conflicting, some report that increased t-tau and p-tau concentrations are associated 
with cognitive impairment in PD229-231 and also motor progression232. Contrary to this, 
others have reported decreased t-tau and p-tau181 concentrations in PD-MCI 
compared with PD with normal cognition187 and PD-MCI compared to controls233. In 
the PPMI cohort increased total tau but not p-tau181 was associated with lower total 
MoCA score after two years of follow-up228. As reviewed by Lin et al, most studies 
find no association between CSF t-tau and p-tau concentrations and cognition223. One 
possible explanation for the discrepancies could be PD duration and severity; evidence 
for the impact of neurofibrillary tangle pathology on cognition come from autopsy 
studies naturally including mostly patients with long disease duration. One study 
found that t-tau and p-tau181 concentrations are higher in older patients with PDD 
than in younger patients with PD and normal cognition231, another that while there was 
no link between p-tau181 concentrations and cognitive decline in very early PD, 
increased p-tau181 was associated with faster cognitive decline after initiation of 
dopaminergic treatment234. Thus, increased t-tau and p-tau181 might be markers for 
extensive AD pathology in PD, this is supported by findings from a study of autopsy 
verified LBD cases – those with an antemortem lower abeta42 and higher t-tau and p-
tau181 concentrations had more AD pathology at autopsy235. In conclusion, although 
there is evidence for the importance of neurofibrillary tangle pathology on cognition 
and prognosis in PD, our finding of no association between cognition and increased 
CSF markers of neurofibrillary tangle pathology in early PD suggest this is less 
important for early cognitive impairment. The neurobiological mechanisms for our 
finding of decreased the t-tau and p-tau concentrations in PD compared to controls are 





Since !-synuclein is the key protein in the development of LBD, it is tempting to 
explore this as a potential CSF biomarker. We found that reduced !-synuclein in CSF 
was significantly associated with impaired global cognition assessed with the 









For an overview of studies exploring the association between CSF !-synuclein and 
cognition, see table 7. Briefly, cognitive impairment has been found to be associated 
with increased !-synuclein132, 236-238, decreased !-synuclein180, 236, 237 and without any 
relationship to CSF !-synuclein concentrations133, 187, 225, 226, 239 in  PD. Of the 12 
studies summarized in the table 8, five included fewer than 50 patients, three between 
50 – 100 patients, the largest studies were the ones by Stewart et al236 with 350 
patients, Goldman et al with 115 patients226 and the studies based on the PPMI cohort; 





The largest study apart from the PPMI, the DATA-TOP trial, included newly 
diagnosed PD patients from 1987 – 1988, thus samples were stored for two decades 
before analysis236. Originally this was a randomized control trial of deprenyl and !-
tocopherol, with a phase one from inclusion to levodopa treatment was needed, and 
phase two after initiation of treatment, average follow up was 1.8 years. In phase one, 
low !-synuclein concentrations correlated significantly with impairment on a 
neuropsychological test of delayed recall. Higher CSF !-synuclein levels at the 
beginning of phase two were associated with faster cognitive decline over phase 
two236. This association between higher !-synuclein levels and faster cognitive decline 
was also found in another study of PD patients on dopaminergic treatment (median 
disease duration seven years)132. High CSF total !-synuclein concentrations correlated 
with impaired cognition (total MMSE score) in another study that likely included PD 
patients mainly on dopaminergic treatment (the proportion of patients receiving 
treatment was not stated, but the median disease duration was 4 years)238. In line with 
our findings of an association between reduced !-synuclein and impairment of 
executive function and attention, Compta and coworkers found that reduced !-
synuclein was significantly associated with impaired phonemic fluency (testing 
executive function) in PD and PDD patients237. In the same study, increased CSF !-
synuclein was associated with impairment of verbal memory and language, but of 
note, these associations were lost when t-tau concentrations were added as a 
covariate237. Of the studies exploring the relationship between cognition and !-
synuclein, the PPMI is the largest, with well-characterized patients, and the study itself 
is designed for assessment of biomarkers.  
 
Initiation of dopaminergic treatment replaces lost dopamine from those areas affected 
by primary dopaminergic deficits such as the putamen, however, areas that do not yet 
suffer from loss of dopamine may be overdosed240. As a result, dopaminergic 
treatment may improve cognitive functions dependent on frontostriatal circuits 




on feedback and trial and error due to an overdose of dopamine240. Thus, if the frontal 
executive/attentional dysfunction we found to be associated with !-synuclein is 
affected by treatment, this could be one explanation for the discrepant findings. This 
would add to all the other differences between the studies that explore the association 
between cognition and !-synuclein; PD patients at different disease stages, cognition 
tested with methods ranging from simple screening instruments (MoCA or MMSE) to 
neuropsychological test batteries, and some studies including follow up while others 
are cross-sectional. CSF α-synuclein has also been found to be decreased in subjects 
with a postural instability/gait difficulty phenotype compared to cases with tremor 
dominant or indeterminate phenotypes180, 226, thus clinical phenotype of the included 
patients could also play a role.  
CSF(!Tsynuclein(as(a(biomarker(
A number of studies have explored the utility of CSF !-synuclein as a biomarker for 
PD, but the results have been conflicting. Both pre-analytical and analytical factors 
probably contributed to the inconsistent results. Commercial assays for the analysis of 
!-synuclein in CSF have been available for a much shorter time than for abeta42, t-tau 
and p-tau181. The concentration of total CSF !-synuclein in PD patients in the studies 
listed in table 8 above range from 110 – 23 000 pg/ml. Different assays were used, and 
to date, there is no accepted standard method. Thus it is by no means certain that these 
studies have measured the same entity, the different antibodies used in the 
immunoassays might have bound to different !-synuclein species.  
 
However, total !-synuclein might not be the most clinically important !-synuclein 
species or the most suitable biomarker. Several !-synuclein aggregates have been 
identified, including soluble oligomers consisting of 2 – 100 !-synuclein monomers81. 
Soluble oligomers might be the toxic agent in LBD241, acting as seeds catalysing the 
transformation of !-synuclein monomers to insoluble fibrils241, 242.  Increased oligomer 
concentrations have been found in brain homogenates of both DLB and PD patients241. 
CSF oligomer concentrations were higher in PD than in AD, PSP and controls227, 238, 




patients from controls with a sensitivity of 89% and a specificity of 91% in one 
study243, and 82% and 64% in another227. Oligomeric !-synuclein concentration has 
also been found to correlate with the severity of motor symptoms in PD238 and to 
increase in the same patients after two years244. When CSF from PD patients was 
added to recombinant !-synuclein, increasing PD severity caused more rapid 
aggregate formation242. More research is needed to determine !-synuclein oligomers 




Our findings from the PPMI study are based on patients shortly after the first clinical 
presentation of neurodegenerative disease, while our neuropathological results are 
mostly patients with severe impairment. It is interesting that patients with both early 
and end-stage disease show evidence of comorbid AD and Lewy body pathology in 
cognitive impairment; newly diagnosed PD patients with MCI had lower CSF abeta42 
concentrations than those with normal cognition and at autopsy ten of 31 patients with 
a neuropathological diagnosis of AD had some degree of Lewy body pathology and 
nearly all the 20 LBD patients had some degree of AD pathology. Decreased CSF 
abeta42 has been found to correlate with increased AD pathology at autopsy in LBD 
patients235. In addition to additive effects of comorbid pathologies, there are evidence 
for interactions at the molecular level16, 245. As my thesis shows, the co-occurrence of 
AD and LBD pathology is common and might prove to be an important factor in the 
neurobiology of neurodegenerative cognitive impairment, further research into 
comorbid pathology and protein interactions should be a priority.  
 
Four patients were clinically diagnosed as AD but proved to have DLB at autopsy. All 
four were without DLB features at baseline, but in three the core features developed 
after two-three years of follow-up. The fact that all false negative DLB patients had 
severe AD pathology with Braak neurofibrillary tangle stage VI supports the notion 





None of the PDD but nine DLB patients had Braak neurofibrillary tangle stage VI. 
Thus four of the patients with diffuse neocortical Lewy body pathology and the most 
severe AD pathology were clinically classified as AD, 5 as LBD. One could argue that 
these are mixed AD-DLB cases, with a clinical phenotype reflecting both the Lewy 
body and AD pathology. So what differentiates these patients, with similar pathology 
but different clinical phenotypes? A neuropathological study of mixed AD-DLB 
patients found that patients that presented as clinical AD had higher neurofibrillary 
tangle load with a different anatomical distribution than those who presented with 
clinical DLB246. In those that presented as AD, the anatomical distribution of 
neurofibrillary tangles was similar to those in pure AD, whilst the cases that presented 
as DLB had less hippocampal neurofibrillary tangles246. This suggests the total burden 
of the different protein aggregates and anatomical distribution could play a role. 
However, it is also important to bear in mind that the neuropathology is the end stage, 
and the temporal development of pathology is unknown. Our results also highlight that 
the core DLB features can develop after the onset of dementia. In patients with 
autopsy verified DLB, only 22% had visual hallucinations, 26% had parkinsonism and 
13% both at the first visit to a secondary care dementia clinic247. Thus the emergence 
of core DLB features in the first years after diagnosis should warrant consideration of 
whether a revision of the clinical diagnosis is necessary. 
False(positive(patients(
Two of the four patients with a clinical DLB diagnosis but AD at autopsy, i.e. false 
positives, had visual hallucinations and severe impairment of vision due to age-related 
macular degeneration. Complex visual hallucinations can occur in persons with 
significant visual impairment in the absence of mental disease110. In autopsy-verified 
cases, the odds of LBD were 4-5 times greater than AD if hallucinations occurred 
during the first 5 years of dementia, but over the whole course of disease 
hallucinations were equally common in AD and LBD109. Misdiagnosis of AD patients 
with early visual hallucinations as DLB has also been reported by others, patients with 
neuropathologically confirmed AD were five times more likely to be misclassified as 




fall into this category, with both having severe AD at pathology (Braak neurofibrillary 
tangle stage VI) without any Lewy body pathology. In LBD, hallucinations have been 
found to correlate with limbic Lewy body density, while in AD early visual 
hallucinations were associated with greater density of limbic and cortical 
neurofibrillary tangles109. Interestingly, our third false positive patient had limbic 
Lewy body pathology in addition to severe AD. The association between limbic Lewy 
bodies and hallucinations has also been found in PD patients without dementia249.  
 
All the false positive patients had gradually increasing UPDRS-III scores, but of note 
two of them had received antipsychotics. One of these two patients was treated with 
risperidone from shortly after diagnosis right up until his death, the dose was increased 
over the years. The DLB criteria require that parkinsonism is spontaneous, not due to 
stroke or antidopaminergic medication62. Whilst these particular patients fulfilled the 
DLB criteria independent of parkinsonism due to visual hallucinations and 
fluctuations, however, use of antipsychotics might lead to misinterpreting drug-
induced parkinsonism for a DLB feature and misdiagnosis.  
The(accuracy(of(clinical(DLB(diagnoses((
In our prospective cohort study, with annual follow up until death, 16 of 20 patients 
with neuropathological DLB were correctly identified, resulting in a sensitivity of 73% 
and a specificity of 93% for the 2005 DLB consortium clinical criteria against autopsy. 
Few other prospective studies have examined the accuracy of the DLB clinical 2005 
diagnostic criteria.  
 
In a systematic review of the literature until October 2016, Rizzo and co-workers 
found a pooled sensitivity, specificity and accuracy of the 1996 criteria in early 
dementia of 19%, 95% and 78% respectively250. Their systematic review included only 
two studies using the clinical 2005 criteria, and those two studies included patients 
with late-stage disease – in both studies diagnosis were re-evaluated until death250. See 
Table 9 for an overview of important publications on diagnostic accuracy in DLB after 




diagnosis without further specification which was not included in Rizzo and co-




In their review, Rizzo and co-workers conclude that the clinical DLB criteria have 
become more sensitive and less specific over time250. The decrease of specificity is 
based mainly on the papers by Fujishiro114 and Ferman116 (see Table 9). However, the 
approach in these two papers makes their results unfit for comparison with standard 
dementia diagnostics. In both papers, diagnoses were re-evaluated yearly until death. 
In the paper by Ferman and co-workers core DLB features were considered present if 
they developed at any time-point116. But, as their study also demonstrates, the core 
DLB features of visual hallucinations, fluctuations and parkinsonism lose their 
specificity for DLB in severe dementia. In the patients with other dementia diseases 
than DLB at autopsy, 40% had fluctuations, 24% had visual hallucinations and 38% 




50% of DLB patients had fluctuations at baseline compared to 29% in the other 
dementia group, and time from estimated dementia onset to visual hallucinations and 
parkinsonism was an average of two years in the DLB group compared to 5 years in 
the other dementia patients116. This was also seen in the paper by Nelson and co-
workers (see Table 9), in patients with relatively severe dementia (mean MMSE 11.4), 
the core DLB features parkinsonism, visual hallucinations and fluctuations did not 
predict neuropathological LBD8.  
 
As study clinicians had a particular emphasis on DLB, and structured rating scales for 
all core DLB symptoms were used, it is likely that we identified more patients with 
DLB than in standard clinical routine. In support of this, we observed differences 
between our recruiting centres. The majority of patients were recruited from three 
outpatient clinics. Notably, three of the four patients with a false negative DLB 
diagnosis were recruited from one centre, where there were no clinicians with a special 
clinical or research interest in DLB. If the 16 patients from this centre were excluded, 
sensitivity and specificity of a clinical DLB diagnosis would increase to 90% and 
100%, respectively. Our clinical diagnostic procedure was based on expert consensus, 
and none of the clinicians in this centre participated in the process. Our results 
demonstrate the limitations of a diagnostic procedure based solely on the assessment 
of standardized measures and case notes without direct contact with the patient. In 
order to be useful, the DLB criteria must be sufficiently robust to be used by clinicians 
without expert knowledge on DLB. Our results also indicate that the 2005 criteria 
perform very well when applied by expert clinicians focusing particularly on DLB, but 
lack sufficient sensitivity outside such centres.  
 
Nelson and co-workers found a sensitivity of 32% and a specificity of 98% for patients 
diagnosed in clinical routine in a large study published in 2009 (see table 9)8. 
Unfortunately, the results by Selvackdunco and coworkers from 2019 indicate that 
sensitivity in clinical routine has not improved over the last decade, as they report a 
sensitivity of 20% and specificity 98%9. It remains to be seen whether the changes 




accuracy. The threshold for parkinsonism was lowered, now only one of the cardinal 
features of parkinsonism are required, this could increase sensitivity. However, it also 
has the potential to decrease specificity and increase the number of false positives, as 
motor symptoms can occur in other dementia116 and cognitive impairment during the 
neurological examination and musculoskeletal conditions might be misinterpreted as 
parkinsonism62.  
 
In conclusion, our findings as well as those by Nelson8 and Selvackadunco9, indicate 
that the clinical DLB criteria are not yet sensitive enough, however, the specificity is 
satisfactory. Evidence to date does not support a decrease in the specificity of clinical 
DLB diagnosis in mild dementia with the introduction of the 2005 DLB criteria, 
however the clinical DLB criteria are unsuitable for differential diagnosis in severe 
dementia. However, as we have shown, the core features may develop during the first 
years after dementia onset in DLB. Future research must ascertain the accuracy of the 
clinical 2017 DLB criteria, and clarify what time-frame between onset of cognitive 
symptoms and core features are consistent and inconsistent with DLB. The 
disappointing sensitivity in clinical routine DLB diagnostics also demonstrates the 
need for biomarkers. Fortunately, both polysomnography and DAT imaging have been 
found to increase the accuracy of clinical DLB diagnosis in autopsy verified cases116, 
136. Increased clinical use would probably increase accuracy. Unfortunately, their use 
is limited by availability and costs. There is a clear need for more easily available 






The main findings in paper I were that CSF t-tau and p-tau181 significantly correlated 
with apathy in early AD. However, no correlations was found between depression and 
psychosis and any markers. The associations found suggests a link between 
neurofibrillary tangle pathology and apathy. Results must, however, be interpreted 
with caution as paper I have limitations, the most important being the small patient 
sample. The neuropathological underpinnings of neuropsychiatric symptoms in AD 
are not yet fully understood, but most likely heterogeneous with a combination of 
psychosocial, individual and neuropathological factors.  
6.2" Paper"II"
The main findings of paper II were the correlation between decreased !-synuclein 
concentrations in CSF and impairment of both global cognitive function and the 
executive function/attention cognitive domain and decreased abeta42 concentrations in 
CSF from PD-MCI patients compared to PD with normal cognition and healthy 
controls. Reduced !-synuclein was also associated at trend level with impairment of 
both memory and visuospatial domains.  
6.3" Paper"III"
The main findings from paper III were that the clinical criteria for probable DLB had a 
sensitivity, specificity, positive and negative predictive values of 73%, 93%, 79% and 
90% respectively, compared to pathological diagnosis. All PDD patients were 
correctly classified. Three patients were false positive, with a clinical DLB diagnosis 
but neuropathological AD. Two of the three had no LBD pathology, but impaired 
vision and visual hallucinations at baseline, highlighting the importance of taking 





Four neuropathological DLB cases were given a clinical AD diagnosis. None had core 
DLB features at baseline, but these developed two–three years into the study in three 
of these patients. All of them had severe AD at autopsy, with Braak neurofibrillary 
tangle stage VI, and could thus be considered mixed AD-DLB cases, highlighting the 
influence of comorbid pathology on the clinical phenotype. Our results show that core 
DLB features can develop after diagnosis and that the sensitivity of a clinical DLB 
diagnosis is probably still suboptimal, especially outside centres with a particular 









We conducted study I out of a conviction that neuropsychiatric symptoms are key 
factors in dementia, and thus must be linked to neuropathology. The importance of 
neuropsychiatric symptoms has since the publication of our paper been confirmed by 
other studies. Late-life neuropsychiatric symptoms such as affective symptoms, 
apathy, and socially inappropriate behaviour increase the risk of dementia more than 
MCI253, increase the risk of progression from MCI to dementia254, 255 and decrease the 
likelihood of reversion from MCI to normal cognition254. Neuropsychiatric symptoms 
are also associated with poor clinical outcomes43, 256-258, increased mortality43, 257 and 
dementia progression43, 257, 258, and there are few treatment options. Understanding the 
mechanisms underlying these symptoms is therefore of the highest importance in order 
to develop new and better treatment strategies for these key features of dementia.   
 
Future research is needed to clarify to what degree there is a link between particular 
pathologies and neuropsychiatric symptoms, and to what degree the same phenotype 
can be explained by several kinds of pathology. For instance, visual hallucinations in 
AD have been found to correlate with both neurofibrillary tangles, vascular lesions and 
Lewy body pathology219, 259, hallucinations are also associated with cerebral amyloid 
angiopathy220.  
7.2" !Psynuclein"as"a"Lewy"body"pathology"biomarker"
Studies exploring the association between cognition and CSF total !-synuclein have 
reported discrepant findings. Total !-synuclein concentrations are highly variable 
between studies, with significant overlap between LBD and controls. As a biomarker 





More research is needed to determine whether !-synuclein oligomers might prove to 
be valuable LBD biomarkers or targets for treatment. One could argue that today’s 
LBD biomarkers such as DAT imaging, polysomnography and low uptake on 
123iodine-MIBG myocardial scintigraphy are markers of the consequences of the !-
synuclein and Lewy body pathology, rather than of the pathology itself. There is a 
clear need for more direct biomarkers of LBD pathology.  
7.3" Diagnosing"dementia"
We reported that the 2005 clinical DLB criteria61 had suboptimal sensitivity. Research 
based on the 2017 criteria62 will show if the changes made, such as lowering the 
parkinsonism threshold and inclusion of RBD as a core criterion, is sufficient to 
increase sensitivity without unacceptable effects on specificity. 
 
The main theme of my thesis has been associations between clinical symptoms and 
neuropathology. Both paper II and III add to overwhelming evidence that concomitant 
pathologies are more the rule than the exception in neurodegenerative cognitive 
impairment. The relationship and potential interaction between pathologies must be 
clarified in the years to come.  
 
Paper III demonstrates that detailed characterization of the clinical phenotype is a 
powerful predictor of neuropathological lesions. However, it also shows that a purely 
clinical approach has major limitations in mixed AD and LBD cases. More severe AD 
pathology increased the risk of patients with LBD pathology being classified as AD, 
comorbid AD pathology in LBD also influence survival and progression of dementia5, 
260. An efficient treatment for one of the proteinopathies will make it imperative to 
detect the pathology actually present, and in mixed cases and likely prodromal cases 
this will require the use of biomarkers. It remains to be seen whether increased 
knowledge from biomarkers about the neurobiological process in the individual 




medicine today; that these neurodegenerative diseases are diagnosed only after the 
emergence of the dementia syndrome and mainly one diagnosis per patients.  
 
Both CSF biomarkers and imaging will likely be important to detect neuropathology in 
vivo. Work is being done to standardize the analysis of CSF t-tau, p-tau181 and 
abeta42 to decrease the variation that hampers efficient use of the markers today7. 
More studies with both careful clinical evaluation and follow-up, biomarker analysis 
and neuropathological evaluation are necessary to clearly establish the association 
between clinical presentation, biomarkers and the contribution of different 
neuropathological lesions.  
7.4" Clinical"implications"
Clinical implications of my thesis include that cognitive impairment is present in a 
significant fraction of patients with early PD, highlighting that PD is not simply a 
movement disorder – not even at disease presentation. This should be taken into 
account in patient care.  
 
Also, the risk of misdiagnosing patients with early DLB as AD is still substantial. 
Even when we applied structured rating scales for all core DLB features and referred a 
subsample to DAT imaging, we only reached a sensitivity of 73% for DLB. 
Selvackdunco and coworkers9 findings corresponds to a sensitivity of only 20% for 
clinical routine DLB diagnosis in the United Kingdom at approximately the same time 
as our Demvest study. The DLB Consortium recommends that structured rating scales 
for fluctuations and RBD are used, DAT imaging in cases where parkinsonism is 
clinically uncertain and polysomnography if there is a doubt as to whether a sleep 
disturbance is RBD. In addition to this, diagnoses should be re-evaluated if the core 
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